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3To my family and to you,
come into my life like a shooting star and, like a shooting star, gone too soon.
“If you can dream it, you can do it.
Always remember that this whole thing was started with a dream and a mouse.”
Walt E. Disney
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ABSTRACT
Breast  cancer  is  the  second  most  common  cancer  in  the  world  and  the  most
common cancer among women. Germ-line mutations in the DNA repair gene
RAD51C (RAD51 paralog C) predispose women to breast and ovarian cancers, yet
the  mechanisms  by  which  a  lack  of RAD51C causes tumorigenesis are poorly
understood. RAD51C deficiency is thought to promote cancer by preventing
correct repair of DNA double-strand breaks, leading to accumulation of somatic
mutations and genomic instability, a cancer hallmark. Similarly, defects in other
genes involved in repair of DNA double-strand breaks, such as BRCA1 (breast
cancer 1, early onset), BRCA2 (breast cancer 2, early onset), or PALB2 (partner and
localizer of BRCA2), are linked to breast cancer, suggesting that the mammary
gland is particularly susceptible to genomic instability.
We  know  that RAD51C-null cells from several organisms present a number of
chromosomal aberrations, and Rad51c knockout mice die during early
embryogenesis from massive Trp53-mediated apoptosis. A previously generated
mouse model demonstrated that when Rad51c is lost together with Trp53, multiple
tumors develop approximately at one year of age. However, while Trp53 knock-
out mice predominantly develop osteo- and myosarcomas, a spontaneous loss of
both Rad51c and Trp53 in double-mutant mice leads mostly to development of
epithelial-derived carcinomas, especially in mammary glands, skin, and skin-
associated specialized sebaceous glands. While suggesting a possible role for
Trp53 in the Rad51c-mediated tumorigenesis, this study left several questions
unaddressed. First, the ability of Rad51c loss to induce tumor formation
independently of Trp53 stood as an open question. Second, the mechanisms by
which Rad51c might cause malignant transformation remained unclear. Last, there
was complete absence of information about the role of Rad51c in the mammary
gland.
vWe set out to fill these gaps by generating a skin and skin-associated Rad51c knock-
out mouse model. For this purpose, we conditionally deleted Rad51c and/or Trp53
from basal cells of the epidermis and ectodermal-derived glands using Keratin 14
Cre-mediated recombination. With this model, we demonstrated that deletion of
Rad51c alone is not sufficient to drive tumorigenesis but impairs the proliferation
of sebaceous cells and causes their transdifferentiation into terminally
differentiated keratinocytes. In addition, we reported that Rad51c/p53 double
mutant mice develop multiple tumors in skin and mammary and sebaceous glands
at around six months of age, while Trp53-mutants have a tumor-free survival of 11
months and a lower tumor burden. We also observed that in situ carcinomas are
detectable in Rad51c/p53 double mutant mice as early as four months of age, which
provided a tool for studying the early phases of tumorigenesis. Notably, we
reported that mouse mammary tumors recapitulate several histological features
of human RAD51C-associated breast cancers, especially a luminal-like, hormone
receptor-positive status. Finally, we described that loss of Rad51c causes
chromosomal aberrations in both mouse and human cells, providing a direct
translational link between the phenotype observed in the two species.
In summary, this thesis: i. confirms that Rad51c is a tumor suppressor and breast
cancer predisposition gene in both human and mouse; ii. describes how Rad51c
causes tumors, focusing on mammary tumorigenesis; and iii. provides a reliable
mouse model of breast cancer that has the potential for exploring therapeutic
approaches specific for human RAD51C-mutation carriers.
11 REVIEW OF THE LITERATURE
Cancer accounts for 20% of deaths worldwide, and approximately 40% of the global
population is newly diagnosed with cancer every year. Cancer is a complex genetic
disorder comprising more than 100 different diseases, and it is caused by genetic
mutations that affect and alter the function of gene products (American Cancer
Society Facts and Figures 2013). These mutations can be caused by exogenous
factors, such as chemical carcinogens, radiation, or oncogenic viruses, as well as
by endogenous factors, such as mutations occurring during DNA replication and
cellular proliferation, and as a result of cellular aging. In addition, mutations caused
by both exogenous and endogenous factors can be inherited and transmitted to
the offspring (Iyama et al, 2013).
Approximately  90%  of  cancer-causing  mutations  usually  result  in  the
activation of a gene product, an encoded protein. Such mutations are dominantly
acting, meaning that the abnormal protein acquires functions sufficient to
contribute to tumorigenesis, even when the wild-type protein is still present.
These genes are called oncogenes.
The remaining 10% of cancer-causing mutations result in the abrogation of
the protein functions and act in a recessive way, therefore requiring the
inactivation of both alleles for initiation of tumorigenesis, following Knudson’s
“two-hit” hypothesis. Such genes are known as tumor suppressors (Knudson,
1995).
1.1 Sporadic cancers and hereditary syndromes
Most cancer-causing mutations occur in somatic cells and are usually classified as
either driver or passenger mutations. Driver mutations are those that actively
2confer a growth advantage to the cell, and therefore are positively selected for as
the cancer develops. Passenger mutations do not confer any growth advantage to
the cell and are either a consequence of the driver mutation or were already
present when the driver mutation occurred (Stratton et al, 2009).
Approximately 5-10% of all cancers are, however, hereditary (Garber at al,
2005). The mutations responsible for hereditary cancers, called germ-line
mutations, are transmitted following Mendelian inheritance and confer to their
carriers a higher life-long risk to develop tumors, compared to the general
population. In addition, carriers of germ-line mutations are also predisposed to an
earlier onset of tumor formation (Chen et al, 2010).
To date, several hereditary cancer syndromes have been described (Table
1). However, while for some of them the underlying responsible gene has been
identified, such as Rb in retinoblastoma (Garber at al, 2005), the currently known
cancer susceptibility genes linked to other syndromes account only for a small
percentage of the cases. The rest of the genes involved in familial cancers are still
poorly characterized.
Table 1. Genes and hereditary cancer syndromes that will be discussed in this study.
syndrome genes prevalent tumors inheritance
Li-Fraumeni syndrome TP53
Soft tissue sarcoma,
osteosarcoma, breast cancer,
leukaemia
dominant
Hereditary breast and
ovarian cancer syndrome
BRCA1,
BRCA2
Breast cancer, ovarian cancer,
pancreatic cancer, prostate
cancer
dominant
Other hereditary breast
cancers
CHK2
PALB2
ATM
RAD51C
Breast cancer
Breast cancer
Breast cancer
Breast (and ovarian) cancer
dominant
recessive
recessive
recessive
Fanconi Anemia FANCA-P Leukaemia, skin cancer,squamous cancer recessive
Muir-Torre and Lynch
syndromes
MHL1,
MSH2,
MSH6
Sebaceous cancer, gastro-
intestinal cancer dominant
31.1.1 Hereditary breast cancer
Breast  cancer  is  the  second  most  common  cancer  in  the  world  and  the  most
common cancer among women (Alteri et al, 2013). Sporadic breast cancer
accounts for about 70% of all diagnosed tumors, while the remaining 30% is
represented by hereditary cancers (Figure 1).  Among these, mutations in the
breast cancer susceptibility genes BRCA1 and BRCA2 account for approximately 40%
of all inherited breast cancers (Olopade et al, 2008). Mutations in BRCA1 and BRCA2
are also responsible for pancreatic, prostate, and especially ovarian cancers
(Marcotte et al, 2012). Furthermore, both genes, BRCA1 and BRCA2, are mutated in
families affected by both breast and ovarian cancers. Compared to the general
population, germ-line carriers of mutations in these genes have an especially high
estimated lifetime breast cancer risk of 60-85%, as well as a lifetime ovarian cancer
risk of 26-54% and 10-23% for BRCA1 and BRCA2 mutations, respectively (Thompson
and Easton, 2004).
Figure 1: Incidence of sporadic and hereditary breast cancers and known susceptibility
genes. Modified from Olopade, 2008.
41.2 DNA damage and repair: pathways of hereditary breast
cancer
Aside from the tumor suppressor TP53, most of the genes responsible for
hereditary breast cancer are those whose products are involved in maintaining
genome stability (Figure 1) (Olopade et al, 2008). The proteins encoded by such
genes are responsible for supervising critical steps of the cell cycle, acting as
sensors and transducers for DNA damage, and most importantly, repairing DNA
damage (Rouse and Jackson, 2002).
The sources of DNA damage can be exogenous or endogenous.
Exogenous sources of DNA damage include exposure to chemicals, radiation, and
viruses. Such exposure results in a wide variety of damage, ranging from direct
crosslinking of bases to oxidation or formation of DNA adducts.  In the case of
endogenous sources, such as generation of reactive oxygen species, the types of
DNA damage include base modifications, such as oxidation, deamination,
depurination and depyrimidation, alkylation, and formation of base analogues and
DNA adducts, from simple to bulky. In addition, endogenous DNA damage can
arise from replication errors, leading to mismatch of bases and stalled replication
forks (Friedberg et al., 2008; Hakem et al., 2008; Liang et al., 2009).
Regardless of the source, DNA damage will lead to two major results:
single-strand breaks (SSBs) or double-strand breaks (DSBs). If not properly
repaired, SSBs can eventually progress into DSBs, which are the most deleterious
of all DNA damage (Bassing et al, 2004).
Several mechanisms have evolved to process the specific types of damage
(Figure  2),  but  due  to  the  deleterious  nature  of  DSBs,  the  most  important
mechanisms are those responsible for repair of DSBs: non-homologous end joining
(NHEJ), homologous recombination (HR) and interstrand cross-link repair (ICL).
5More specifically, NHEJ is active throughout the cell cycle, predominantly
during G0 and G1, but is error-prone (Sonoda et al, 2006), while HR is an error-free
mechanisms active in S and G2 phase and utilizes the sister chromatid as a
template for repair (San Filippo et al, 2008). Interstrand crosslinks are processed
first by the ICL pathway and successively by nucleotide excision repair (NER) (Kim
and D’Andrea, 2012) and HR or NHEJ, depending on the cell cycle phase (Mladenov
et al, 2009).
Dysfunctions in HR and ICL repair have been associated with both sporadic
and hereditary breast cancers as well as breast and ovarian cancer syndromes
(Liang et al, 2009; Deans and West, 2011; Kasparek and Humphrey, 2011).
6Figure 2: DNA  repair  pathways  and  proteins  involved  in  cancer  development.
Modified from Bouwman, 2012.
71.2.1 Homologous recombination
Homologous  recombination  is  the  only  currently  known  error-free  pathway  for
repairing DNA DSBs (Li and Heyer, 2008). It is highly conserved, from bacteria to
plants and from yeast to animals. In addition, some DNA viruses (e.g.
herpesviruses) and single-strand RNA viruses (e.g. some retroviruses) have a
homologous recombination mechanism for repairing damage. Taken together, it
is clear that this particular pathway plays an important, conserved role in
maintaining genome stability (Lin et al, 2006).
In eukaryotes, homologous recombination is essential for the repair of
DSBs, as well as telomere maintenance and correct chromosome segregation in
meiosis I (Tacconi and Tarsounas, 2014; Holliday, 2007).
Homologous recombination (Figure 3) is a highly controlled mechanism
that utilizes the sister chromatid as a template to re-synthesize the damaged
sequence. For this reason, homologous recombination is restricted, in mitotic
cells, to S and G2 phase (San Filippo et al, 2008), due to the tightly time-regulated
gene expression of several HR proteins.  For example, MRE11, RAD54 and RAD51
are regulated in a cell-cycle dependent manner and become available only after
DNA synthesis (Heyer et al, 2010; Jasin et al, 2013; Mjelle et al, 2015).
When a DSB is generated, the damage is sensed by the MRE11-RAD50-NBS1
complex (MRN) (Iyama et al, 2013). The recruitment of this complex, in addition to
changes in chromatin structure, triggers NBS1-mediated phosphorylation of the
Ataxia Telangiectasia Mutated kinase (ATM), which, in turn, undergoes
autophosphorylation and phosphorylates the MRN complex, amplifying the initial
signal (Branzei and Foiani, 2008). Once ATM is active, it rapidly induces both cell
cycle arrest and HR initiation by phosphorylating the Ser139 residue near the C-
terminus  of  histone  H2Ax.  The  formation  of  phospho-H2Ax  (γH2Ax)  leads  to
phosphorylation of adjacent H2Ax histones, forming a “γH2Ax focus,” thereby
8enhancing  the  signal  to  quickly  recruit  other  HR  proteins  at  the  site  of  the  DSB
(Scully and Xie, 2013).
Indeed, γH2Ax focus detection is commonly used to visualize and quantify DSBs
(Deans and West, 2011). The presence of γH2Ax at sites of damage is required for
recruitment, activation and anchoring of Mediator of DNA Damage Checkpoint
protein 1 (MDC1) which, in turn, recruits and phosphorylates the Checkpoint
effector Kinase CHK2 (Houtgraaf et al, 2006). Activation of CHK2 rapidly induces
an arrest at the S/G2 transition of the cell cycle, by directly inhibiting Cdc25/Cdk1,
thus allowing time for DNA repair (Niida and Nakanishi, 2006). In addition, ATM
induces activation and localization of the nuclease CtIP to the DSB to initiate,
together with the nuclease MRE11, the end resection of the damaged DNA. Once
the endonucleases have generated 3’ ssDNA overhangs, the Bloom helicase (BLM)
unwinds the single strand and prevents the formation of secondary structures. At
the same time, Replication Protein A (RPA) is recruited to coat and protect the free
ends from uncontrolled nuclease activity (You et al, 2010; Medema et al, 2012).
Subsequently, end resection is extended by the exonucleases EXO1 and DNA2,
while RPA continuously coats the ssDNA generated (Heyer et al, 2010).
Both the presence of ssDNA and RPA recruits and activates ATM-related
kinase (ATR), which together with MDC1 phosphorylates and activates CHK1
kinase. Similar to CHK2 described above, phosphorylated CHK1 leads to rapid
degradation of Cdc25/Cdk1 and 2, causing cell cycle arrest (Niida and Nakanishi,
2006). Once the cell cycle has been halted, several other proteins, including BRCA1,
are recruited to the DSB. ATM-dependent phosphorylation of BRCA1 at Ser1423
leads to inhibition of the endonuclease activity of the MRN complex and directly
binds to Partner and Localizer of BRCA2 (PALB2) and BRCA2 itself, one of the key
proteins in HR pathway (Cortez et al, 1999). PALB2 forms a complex with BRCA2
and  stabilizes  and  enhances  the  activity  of  BRCA2.  Stabilized  BRCA2  binds  the
RAD51 recombinase, through interaction with the BRC repeats, loads it onto the
ssDNA, and displaces RPA (Zhang et al, 2009).
9In mammalian cells, five proteins related to RAD51, known as RAD51
paralogs, are essential for successful HR (Suwaki and Tarsounas, 2011). These are
RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3.  In different combinations, these
five proteins are known to form two distinct complexes: the BCDX2 complex,
composed  by  RAD51B,  RAD51C,  RAD51D  and  XRCC2,  and  the  CX3  complex,  a
heterodimer of RAD51C and XRCC3. In addition, in meiotic cells, another member
of the family, DMC1, is active (Masson et al, 2001; Henning et al, 2003; San Filippo
et al, 2008). Once RAD51 has coated the ssDNA, thus generating a nucleoprotein
filament, the first of the RAD51 paralogs complex, the BCDX2, ensures filament
stabilization. In addition, the recruitment of the BCDX2 complex facilitates strand
invasion and homology searching on the sister chromatid, performed by the motor
protein RAD54 (Chun et al, 2013). When a homologous sequence is found,
helicases unwind the dsDNA (double-stranded DNA), a D-loop structure forms, and
synthesis of new DNA using the sister chromatid as template occurs. These events
lead to generation of an intermediate cross-stranded DNA molecule typical of the
HR pathway, called the Holliday junction (HJ) (San Filippo et al, 2008), which may
result in chromosomal crossover. Crossover is the exchange of genetic material
between chromosome arms and can happen during meiosis, mitosis and DNA
repair (Neale and Keeney, 2006). However, while meiotic crossover occurs
between homologous chromosomes and is required to generate genetic diversity,
crossover in somatic cells happens between sisters chromatids and can lead to
chromosomal rearrangements and loss of heterozygosity (LOH) (San Filippo et al,
2008).
In order to avoid crossover in somatic cells, the extended D-loop
generated during HR repair is reversed and annealed with the second end of the
DSB, in a process called synthesis-dependent strand annealing (SDSA) (Iyama et al,
2013). Such a sub-pathway (Figure 3, step 6b) is predominant in somatic cells, as it
does not generate crossover products, thus reducing thus the possibility for LOH.
Alternatively, another sub-pathway characterized by second end capture and DNA
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synthesis, results in double D-loop formation and generation of a double HJ (dHJ)
(Figure 3, step 6a). The generation of a dHJ may result in crossover products and
is, therefore, avoided in somatic cells. However, such intermediates are common
in meiotic cells, where the recombinant products are preferred. In both cases, HJ
intermediates are eliminated by a helicase and topoisomerase (BLM-TOPOIII)
complex or by enzymes that introduce one-stranded symmetrical cleavages at the
site of the HJ, called resolvases (Heyer et al, 2010; Iyama et al 2013). In humans,
two complexes, the GEN1-SLX1-SLX4 and MUS81-EME1 complexes, which process
nicked HJs, are currently known to possess resolvase activity (Kass et al, 2010;
Ciccia et al, 2010; Liu et al, 2014). The result of BLM-TOPOIII activity is called
“dissolution” and does not generate crossover products (Kaspared and
Humphrey, 2011), while the resolvase complexes result in formation of both
crossover and non-crossover products, in a process called “resolution” (Heyer et
al, 2010).
The second of the RAD51 paralog complexes, the CX3 complex, composed
of RAD51C and XRCC3, is essential for the correct resolution of HJs, but it does not
possess resolvase activity (Sharan and Kuznetsov, 2007).
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1.2.2 Interstrand cross-link repair
Interstrand cross-links (ICLs) are covalent bonds between bases on opposite DNA
strands and lead to replication fork stalling and inhibition of DNA strand
separation, ultimately resulting in blocking replication and transcription (Heyer et
Figure 3: Pathways of DSB repair. Modified from Liu, 2014.
12
al, 2010; Deans and West, 2011). ICLs are caused by so-called cross-linking agents,
such as nitrogen mustards (i.e. cyclophosphamide), cisplatin, mitomycin c and
alkylating agents. Several cross-linking agents are widely used in modern cancer
treatment (Branzei and Foiani, 2008).
ICLs are repaired by the interstrand cross-link repair pathway. Defects in
such repair mechanism are linked to Fanconi anemia (FA), a syndrome
characterized, with varying degrees of severity, by i. multiple congenital and
skeletal abnormalities, ii. haematological defects such as bone marrow failure,  in
its most severe form, iii. endocrine and fertility dysfunctions, iv.  high  levels  of
insulin, and v. Type 2 diabetes. In addition, FA patients are highly predisposed to a
variety of cancers, especially leukaemia, head and neck squamous cell carcinoma,
and breast/gynaecological malignancies. Due to its association with FA, the ICL
repair pathway is commonly known as the FA pathway (Figure 4) (Deans and West,
2011; Kee et al, 2012; Kim and D’Andrea, 2012).
To-date, at least 16 proteins are recognized as FA proteins: FANCA, FANCB,
FANCC, FANCD1 (BRCA1), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (BRIP1),
FANCL, FANCM, FANCN (PALB2), FANCO (RAD51C), FANCP (SLX4) and FAN1.
Several other proteins are associated with the pathway, acting as scaffolding and
stabilizing proteins (FAAP20, FAAP24, FAAP100, MHF1 and MHF2) or
deubiquitinating proteins (UAF1 and UPS1). The central proteins are FANCD2 and
Figure 4: FA pathway of ICL repair. Modified from Kee, 2012.
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FANCI, which are targets of the FA core complex, composed of FANCA, FANCB,
FANCC, FANCE, FANCF, FANCG, FANCL and FANCM (Deans and West, 2011).
When an ICL is detected, a mechanism led by ATR-CHK1 initiates repair
signalling, as in the initial stage of HR (Figure 4, step 1).  The core protein FANCM,
together with other core proteins, becomes phosphorylated by ATR-CHK1. In turn,
phosphorylated FANCM stabilizes ATR-CHK1 and contributes to S phase
checkpoint activation. The assembly of the FA core (Figure 4, step 2), together
with the associated scaffold proteins, leads to monoubiquitination of FANCD2 and
FANCI, causing the recruitment of the nucleases FAN1 and FANCP (SLX4) (Figure
4, step 3).  Subsequently, FANCP (SLX4) associates with its scaffold partner SLX1
and recruits the nuclease complex MUS1-EME1, resulting in the unhooking of the
ICL (Figure 4, step 4). The DNA adducts are then removed by the nucleotide
excision repair  mechanism (NER),  and the gap is  filled with polymerases.  At the
same time, unhooking of the ICL causes a DSB on the other DNA strand, triggering
activation of HR (Figure 4, step 5), mediated by the phosphorylation of BRCA1, and
the  coating  of  the  ssDNA  by  RPA  (section  1.2.1).  Phosphorylated  BRCA1  recruits
and assembles - through interaction with FANCJ (BRIP1) - FANCD1 (BRCA2), FANCN
(PALB2) and FANCO (RAD51C), as well as RAD51, resulting in a D-loop formation
and recombinational repair (Moldovan and D’Andrea, 2009; Kee et al, 2012).
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1.3 Functions of RAD51C
RAD51C is a member of the recA/RAD51 recombinational gene family (Dosanjh et al,
1998). Members of this family are found in both prokaryotes and eukaryotes and,
while sharing several structural similarities, their functions have specialized and
differentiated during evolution. It is believed that events of gene duplication and
endosymbiosis of the
ancestral recA gene are
the origin of the family
(Figure 5 and 6) (Lin et al,
2006). In fact,
phylogenetic analysis
reveals that three major
clades are found across
the three domains of life:
recA, RADα and RADβ.
Both RADα and RADβ
clades are likely the result of gene duplications that occurred in the common
ancestor of Archaea and eukaryotes (Figure 6). A further duplication of the RADα
gene led to generation, in eukaryotes, of RAD51 and  the  meiotic DMC1, while
multiple duplications of RADβ resulted  in  the  formation  of RAD51B, RAD51C,
RAD51D, XRCC2 and XRCC3 (in animals). While the two RADα-like proteins have
highly conserved ATP-dependent DNA binding and DNA-dependent ATPase
activities, the members of the RADβ clade are characterized by diverse, non-
redundant functions, most likely as a direct result of gene duplication.
Figure 5: Domains and structures of selected
recA/RAD51-like proteins. Modified from Lin, 2006.
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Human RAD51C (Figure 7) is a 375 amino acid long protein, although at
least two other protein variants are described (Dosanjh et al, 1998). RAD51C shares
25 to 39% of its sequence with RAD51 and other RAD51 paralogs (Lin et al, 2006).
Mouse RAD51C (Figure 7) exists as two isoforms as a result of alternative splicing,
resulting in proteins containing 388 and 366 amino acids. Both human and mouse
RAD51C contain a few conserved domains characteristic of the recA-like proteins:
the Helix-hairpin-Helix (HhH) for DNA binding; Walker A and Walker B domains for
ATP binding; BRC domains for interaction with other RAD51 paralogs and possibly
direct interaction with RAD51 (Dosanjh et al, 1998; Strausberg et al, 2002). In
addition, RAD51C possesses a nuclear localization signal (NLS) at its C-terminus
(Gildemeister et al, 2009).
1.3.1 Role of RAD51C in DNA repair
As previously mentioned (sections 1.2.1 and 1.2.2), RAD51C plays a role in both the
HR and FA DNA repair pathways (Moldovan and D’Andrea, 2009; Kee et al, 2012;
Somyajit et al, 2012). In HR, RAD51C is found in both of the RAD51 paralog
complexes (section 1.2.1). In the BCDX2 complex, RAD51C interacts directly with
RAD51B at the C-terminus and with RAD51D at the N-terminus (Masson et al, 2001;
Figure 7: Schematic representation of human and mouse RAD51C.
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Suwaki and Tarsounas, 2011). The formation of this complex is essential for the
generation of RAD51-DNA nucleoprotein filaments. Depletion of any of the
paralogs results in impairment of RAD51-focus formation (section 1.2.1). In
particular, several studies have demonstrated that depletion of RAD51C affects the
HR pathway. Gene expression silencing or inactivation of RAD51C in human tumor-
derived HeLa, HT1080 and Capan-1 cells caused a decrease in complex formation
and localization of RAD51 and, ultimately, impaired recombinational repair (Lio et
al, 2004; Gildemeister et al, 2009). Experiments in Chinese hamster CL-V4B cells
and in the RAD51C-mutant irs3 cell line revealed sensitivity to γ-irradiation,
reduction of sister chromatid exchange, and elevated chromatid breaks (French et
al, 2002), while a study in chicken DT40 cells highlighted reduced RAD51-focus
formation, sensitivity to mitomycin c, and spontaneous chromosomal aberrations
(Takata et al, 2001). The reduction in RAD51 focus formation reflects the
importance of the BCDX2 complex and RAD51C in early stages of HR. In fact,
RAD51C is known to localize at DSB foci within minutes of the DNA damage, and it
facilitates the loading of RAD51 onto the damage site. However, RAD51C-
containing foci persist even after RAD51 has disappeared from the site of the DSB,
consistent with a role of RAD51C in the late stage of HR (Badie et al, 2009). While
it is not clear if the same RAD51C molecules that were part of the BCDX2 complex
will remain to form the CX3 complex, RAD51C presence is essential for successful
resolution/dissolution of the HJ (Liu et al, 2004). Importantly, unresolved HJs
increase physical tensions at centromeres, resulting in chromosomal aberrations
and breaks that may alter genome integrity and lead to i.e. tumorigenesis. For
these reasons, RAD51C is recognized as a key protein of the HR pathway.
In  the  FA  pathway,  RAD51C  is  also  known  as  FANCO,  and  its  role  is  less
characterized; however RAD51C/FANCO is clearly not part of the FA core complex,
nor is it required for monoubiquitination of FANCD2 and FANCI or for the
unhooking of the ICL (Figure 4).  Nevertheless, it is essential for the HR step of the
ICL repair pathway (Somyajit et al, 2010). In fact, Rad51c-mutant Chinese hamster
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CL-V4B cells are extremely sensitive to cross-linking agents, such as cisplatin and
mitomycin C, and their metaphase chromosome preparations are characterized by
a high frequency of radial chromosomes and chromosomal breaks (Somyajit et al,
2012). In addition, RAD51C has been shown to form a complex with BRCA2, PALB2
and RAD51, called “HR complex”, through direct protein-protein interaction with
the PALB2 WD40 domain. Disruption of this complex causes increased sensitivity
to ionizing radiation, reduced formation of RAD51 foci, and an overall impairment
in HR activity (Park et al, 2013). Remarkably, mutations in RAD51C, BRCA2 and PALB2
are found in both breast/ovarian cancer patients and in mild forms of FA, possibly
because of their dual role in HR and in FA pathways.
Finally, RAD51C activity is important for meiotic recombination. In meiotic
cells, RAD51C localizes to MLH1 foci, which are considered a marker for crossover
sites (Baker et al, 1996). The absence of Rad51c in mouse spermatocytes leads to
failure to proceed beyond prophase I and to chromosomal breaks, while in oocytes
it causes precocious sister chromatid separation (PSCS) at metaphase II, resulting
in reduced fertility in both sexes (Kuznetsov et al, 2007).
1.3.2 Role of RAD51C in genome integrity
Due to its role in DSB and ICL repair, RAD51C is required to maintain genome
integrity (Suwaki and Tarsounas, 2011). In addition, several studies have revealed
other functions unrelated to recombinational repair, such as centrosome number
maintenance (section 1.3.2.1), telomeres protection (section 1.3.2.2) and
checkpoint signalling (section 1.3.2.3).
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1.3.2.1 Centrosome number maintenance
Centrosomes are cellular organelles that act as a microtubule-organizing centre,
ensuring correct chromosome segregation during cell division, in order to prevent
aneuploidy. Centrosomes are also involved in regulation of the cell cycle.
Dysfunction in centrosomal activity has been described for a variety of human
diseases, especially cancer (Albertson et al, 2003). In particular, centrosomes are
often subject to amplification and fragmentation, leading to the formation of
multipolar mitotic spindles and chromosomal aberrations. Centrosomal
amplification has been linked to DNA damage, as supernumerary centrosomes are
found in cells exposed to ionizing radiation and this phenotype is dependent on
the ATR-CHK1 signalling, because inhibition of ATR and/or CHK1 can prevent
ionizing radiation-induced centrosome amplification (Dodson et al, 2004; Carr et
al, 2013). However, defects in other proteins belonging to the DNA repair system
can affect centrosome number maintenance. In fact, lack of RAD51C in Chinese
hamster cells has been linked to centrosome amplification in mitosis (Renglin
Lindh et al, 2007), and experiments in human cancer cells have revealed that
RAD51C-induced centrosomal amplification can be also detected in interphase,
leading to a two to seven-fold increase in binucleated cells (Katsura et al, 2009).
Such aberrations are triggered by the ATR-CHK1 pathway, because gene silencing
of ATR can prevent supernumerary centrosome formation in RAD51C-depleted
cells (Katsura et al, 2009). However, RAD51C depletion does not cause centrosome
fragmentation, as described for defects in XRCC3 and the recombinase GEN1
(Rodrigue  et  al,  2013),  or  for  RAD51B  (Date  et  al,  2006).  While  the  mechanisms
leading to centrosomal fragmentation are not fully understood, such process is
thought to be caused by premature centriole disengagement or pericentriolar
material (PCM) fragmentation (Maiato et al, 2014). Both centriole disengagement
and PCM fragmentation are likely to derive from weak or faulty checkpoint
activation (Maiato et al, 2014). Thus, the bias towards centrosome amplification,
rather than fragmentation, described in RAD51C depleted cells may be attributed
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to the fact that, because RAD51C plays a role both in early and late stages of HR,
its depletion triggers a robust cell cycle arrest, allowing more time for repair.
1.3.2.2 Telomere protection
Telomeres are complexes of G-rich DNA sequences and proteins present at the
ends of linear chromosomes, which ensures their protection from deterioration or
fusion, and therefore are important for genome stability (Shen et al, 2009). Several
proteins are known to form the telomeric cap, a structure that protects these G-
rich ssDNA segments from erosion or recombination.
In addition to the cap proteins, several players of the HR pathway, such as
RAD51D and RAD54, have a role in telomere maintenance and have been shown to
promote HR at telomeres (Tarsounas and West, 2005; Verdun and Karlseder,
2007). Specifically, RAD51 plays a central role in telomere protection (Le et al, 1999;
Grandin et al, 2003). In fact, RAD51-deficient mouse embryonic fibroblasts (MEFs)
are characterized by shortening of telomeres (Badie et al, 2010). Consistent with
their RAD51 loading activity, BRCA2 and RAD51C deficiencies also lead to telomere
shortening in MEFs, and defective RAD51 loading causes an increase in multiple
telomere signals (MTSs), a marker of telomere fragility leading to replication fork
stalling and breaks at G-rich sequences. Delays in the DNA damage response are
also responsible for persistent uncapping of telomeres, which can lead to end-to-
end fusion of chromosomes (Badie et al, 2010).  Moreover, human BRCA2-deficient
breast cancers are also characterized by shortening of telomeres (Badie et al,
2010), suggesting that the telomere protection function of HR proteins is required
to prevent tumorigenesis.
20
1.3.2.3 Role of RAD51C in cell cycle checkpoints
DNA replication and repair are tightly regulated throughout the cell cycle by
checkpoints, control mechanisms that ensure correct cellular division. In
eukaryotic cells, four checkpoints are known: the G1 checkpoint, also called the
“restriction  checkpoint”,  which  ensures  that  the  cell  is  fit  to  undergo  DNA
synthesis; the intra-S checkpoint, which is responsible for halting DNA replication
if damage is detected; the G2/M checkpoint, which ensures that DNA has been
properly replicated before cell division; and the M checkpoint, called “spindle
assembly  checkpoint”,  which  delays  cell  division  if  the  mitotic  spindle  is  not
correctly assembled (Figure 8) (Houtgraaf et al, 2006; Schmitt et al, 2007; Branzei
and Foiani, 2008).
Since HR utilizes the sister chromatid produced during S phase as a
template  for  DNA  repair,  defects  in  HR  pathway  are  known  to  trigger  a  G2/M
arrest. Several experiments in chicken, hamster, mouse and human cells confirm
that RAD51C deficiency leads, indeed, to a block at the G2/M transition (Takata et
al, 2001; French et al, 2002; Godthelp et al, 2002; Lio et al, 2004; Badie et al, 2009;
Gildemeister et al, 2009).
In addition, studies have shown that RAD51C has HR-unrelated functions
and is required for both
DNA damage checkpoints.
For example, Rad51c-
deficient hamster CL-V4B
cells treated with
camptothecin (CPT), a
TopoI inhibitor that
causes conversion of SSBs
into DSBs during S phase,
progress faster into M
Figure 8: Simplified representation of eukaryotic
cell cycle checkpoints.
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phase, while Rad51c-proficient cells accumulate in S phase to allow DNA repair.
Moreover, the same treatment prevents replication in wild-type HeLa cells, while
RAD51C-deficient HeLa cells undergo robust DNA replication, indicating a defective
intra-S checkpoint (Somyajit et al, 2012). Furthermore, RAD51C is required for
activation and phosphorylation of CHK2 in an ATM/NBS1-dependent manner,
which is necessary for the G2/M checkpoint (Badie et al, 2009). Here, activation of
ATM by NBS1 causes accumulation of RPA at the DSB site (section 1.2.1 and Figure
3) (Sigurdsson et al, 2001). RAD51C is also recruited at very early stages, because it
co-localizes with RPA foci in irradiated cells (Badie et al, 2009). However, RAD51C
is not required for RPA accumulation, but downregulation of RPA abrogates the
recruitment  of  RAD51C.  Once  more,  CHK2  but  not  CHK1  phosphorylation  is
facilitated by RAD51C, leading to a G2/M arrest and allowing time for loading of
RAD51 by BRCA2, which initiates the DNA repair (Badie et al, 2009).
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1.4 RAD51C is a breast cancer susceptibility gene in humans
Germ-line mutations in several genes involved in DNA repair are associated with
an increased predisposition to breast or breast/ovarian cancer (Meindl et al, 2010;
Loveday et al, 2012; Pelttari et al, 2011; Schnurbein et al, 2011). Nearly 40% of
hereditary breast cancer patients are carriers of mutant BRCA1 or BRCA2, and up to
10% of cases are caused by defects in other known genes (section 1.1.1 and Figure
1). Thus, in approximately 50% of patients with hereditary breast cancers, the
causes are still mostly unknown.
In recent years, significant progress has been made with genome
sequencing and genome-wide association studies (GWAS), leading to
identification of new genes, loci, and SNPs linked to breast cancer (Olopade et al,
2008). One of the genes identified in these studies was RAD51C (Meindl et al, 2010).
Not surprisingly, direct links between RAD51 paralogs and tumors have previously
been reported. For example, several polymorphisms in RAD51 have been
associated  with  breast  cancer  (Lose  et  al,  2006;  Hosseini  et  al,  2013); RAD51B is
often inactivated in benign uterine leiomyomas (Schoenmakers et al, 1999;
Takahashi et al, 2001); and RAD51D has been linked to ovarian cancer (Loveday et
al, 2011).
Figure 9: Pedigree of
breast/ovarian cancer
family with RAD51C germ-
line mutation. Black circles
represent patients with
breast/ovarian cancer.
Other cancers are marked
in gray. Br: breast, Bone:
bone, Es: esophagus, Leu:
leukemia, Ov: ovarian,
Neck: neck, Pro: prostate,
Sp: spinocellular. From
Vuorela, 2011.
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An initial screening in 1100 women with a pedigree of hereditary breast and
breast/ovarian cancer negative for mutations in BRCA1 and BRCA2, revealed 14
mutations in RAD51C, including splice-site mutations, frameshift insertions and
missense mutations, all leading to inactivation of the protein (Meindl et al, 2010).
The presence of such mutations was associated with a mean age of onset of 53
years for breast cancer and 60 years for ovarian cancer, thus slightly longer than
for BRCA1 and BRCA2 patients (40 and 46 years for breast and 49 and 58 years for
ovarian cancer, respectively) (Meindl et al, 2010). Subsequent studies have
identified other predicted deleterious mutations in RAD51C, some of which have
also been functionally validated (Clague et al, 2011; Vuorela et al, 2011; Osorio et al,
2012).
To date, germ-line mutations in RAD51C have been found in families with
hereditary breast/ovarian cancers (0.3 to 0.5%, compared to the general
population) (Osorio et al, 2012) and only ovarian cancers (2.9%) (Cunningham et al,
2014), but not significantly in families with only hereditary breast cancer (Figure 9).
A clinicopathological study of breast cancers from germ-line mutation carriers
revealed that RAD51C mutated tumors are predominantly moderately
differentiated carcinomas belonging to the “luminal A” subtype, hormone
receptor-positive but HER2 (Erb-B2 avian erythroblastic leukemia viral oncogene
homolog 2) negative. According to this classification, RAD51C-related breast
cancers would be more similar to BRCA2- than BRCA1-associated tumors, possibly
with a more favourable prognosis (Gevensleben et al, 2014). On the other hand,
several studies describe RAD51C-associated hereditary ovarian cancers as high-
grade, poorly differentiated serous adenocarcinomas, histologically
indistinguishable from sporadic cases (Pelttari et al, 2011; Cunningham et al, 2014).
In addition to breast and ovarian cancer, mutations of RAD51C have also
been linked to other tumors, such as head and neck squamous cell carcinoma
(HNSCC) and pancreatic cancer, and the RAD51C-containing locus 17q22 was
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reported to be amplified in testicular germ cell cancer (Gresner et al, 2014;
Scheckenbach et al, 2014; Pelttari et al, 2011; Chung et al, 2013).
Moreover, a homozygous missense mutation in RAD51C was  found  in  a
family where several members are affected by a FA-like disorder (Vaz et al, 2010).
Functional analysis of the mutant protein revealed that the R258H amino acid
substitution most likely affects a BRC oligomerization domain (Figure 7), thus
impairing the formation of the three RAD51C complexes: BCDX2, CX3 and the “HR
complex” active in the ICL repair pathway (sections 1.2.1 and 1.3.1) (Park et al, 2013).
The discovery of this missense mutation, in addition to the deleterious mutations
found in hereditary breast cancer patients, confirms that RAD51C is a tumor
susceptibility gene in humans, with key roles in both HR and FA pathways.
1.5 Rad51c is a tumor suppressor gene in mice
Due of the association of RAD51 paralogs with cancer and other diseases, several
attempts to study the functions of these proteins in vivo have been made.
However, mice lacking the genes for Rad51, Rad51b, Rad51d and Xrcc2 genes all
display early embryonic lethality with various degree of severity. The most severe
phenotype derives from Rad51 deficiency, as null embryos fail to develop further
than the blastocyst.  Furthermore, embryonic stem cells (ESCs) derived from their
outgrowths  fail  to  survive  in  culture  (Tsuzuki  et  al,  1996).  Knock-out  mouse
embryos for Rad51b, Rad51d and Xrcc2 are also characterized by early embryonic
lethality at E8.5, E11.5 and E12.5, respectively (Shu et al, 1999; Pittman et al, 2000;
Deans et al, 2000; Adam et al, 2007). In addition, ESCs or primary MEFs isolated
from these null embryos either fail to proliferate in vitro or are affected by severe
growth delay; they are particularly sensitive to DNA damaging agents such as γ-
irradiation and mitomycin c and characterized by high frequency of chromosomal
breaks and aberrations. In all cases, null embryos for RAD51 paralogs suffer from
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elevated p53-mediated apoptosis. In fact, the lethality of Rad51b and Xrcc2 knock-
out can be partially rescued in a p53-null background. As double knock-out
embryos develop further than single knock-out, and MEFs or ESCs derived from
such double knock-outs could be established. However, no full knock-out embryos
of RAD51 or its paralogs are viable, confirming an essential role for the RAD51
family in development.
Attempts to generate knock-out mice for Rad51c have also been made, with similar
results. Complete knock-out of Rad51c resulted in embryonic lethality by day E8.5,
and cells from such embryos failed to proliferate in vitro, as a result of robust p53-
induced apoptosis. Accordingly, double knock-out embryos progressed a little
further, until E10.5 (Kuznetsov et al, 2009).
In a further attempt to obtain a viable mouse, a hypomorphic allele was
created  by  insertion  of  a neo cassette into the first intron of Rad51c (Figure 10)
(Kuznetsov et al,
2007). Such insertion
resulted in a reduction
of approximately 60%
of RAD51C protein
levels, which was
further reduced to
about 20% when
combined with the knock-out allele. Viable mice with the Rad51cneo/ko genotype
could be readily obtained, indicating that the residual RAD51C protein is
compatible with viability. However, 37% of males and 12% of females were infertile.
Histological analyses showed underdevelopment of testes and apoptosis in
spermatocytes, while ovaries lacked corpora lutea, an indication of ovulatory
failure. A closer examination revealed that both spermatocytes and oocytes suffer
from meiotic defects and chromosomal aberrations, which are caused by Rad51c
deficiency. Besides the infertility, however, the hypomorphic mice did not develop
Figure 10: Schematic representation of the first four Rad51c
exons in the wild-type, hypomorphic (neo) and knock-out
(ko) allele. From Kuznetsov, 2007.
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tumors, indicating that even low levels of RAD51C are sufficient to ensure genome
stability.
Since apoptosis in Rad51c null mice is triggered by p53-activation, double
heterozygous (DH) mice for Rad51c and p53 (Rad51c ko/+; Trp53 ko/+) were generated,
in  order  to  obtain  fertile  and  viable
animals  (Kuznetsov  et  al,  2009).  Due  to
the fact that Rad51c and Trp53 are  both
located on mouse chromosome 11 and
are only 10 cM apart, they behave as a
single locus and are inherited together,
thus leading to the generation of two types of DH: i. DH-cis, when both mutant
alleles are on the same chromosome; ii. DH-trans, when they are on two different
chromosomes (Figure 11). As a result, the DH mice successfully developed tumors,
but with different latencies, depending on sex and genotype.
Inactivation of a tumor suppressor, such as p53, in a heterozygous
background, by loss of the wild-type allele is a common step towards
tumorigenesis (Harvey et al, 1993). This event, called “loss of heterozygosity”
(LOH), can be readily detected in tumors derived from Trp53 ko/+ mice, mostly
represented by osteo- and myosarcomas, mammary carcinomas, and
hematopoietic malignancies such as lymphomas. However, LOH of the wild-type
allele of Trp53 led to different outcomes in DH mice.  Specifically, DH-trans animals
lost the knock-out allele of Rad51c and retained the wild-type one, while DH-cis
animals lost the wild-type allele and retained only the mutant Rad51c and Trp53. As
a result, DH-trans mice developed tumors that were indistinguishable from Trp53
ko/+ mice, both in latency and in spectra. In contrast, DH-cis mice developed
predominantly epithelial-derived malignancies, such as mammary and skin
carcinomas in females and tumors of specialized sebaceous glands in males. The
gender-specific tumor spectrum was reflected in cancer-free survival, which was
Figure 11:
Schematic  representation  of  the  DH
model. From Kuznetsov, 2009.
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reduced in females and slightly extended in males, as a result of a shift towards or
away from more aggressive malignancies, respectively.
The generation of the DH model provided convincing evidence that Rad51c
is a tumor suppressor in mice, but a concomitant loss of Trp53 is required for tumor
initiation. In addition, DH-cis animals revealed a predisposition towards epithelial
tumors,  with a 30% increase in mammary carcinomas, which is  consistent with a
role of RAD51C as a breast cancer susceptibility gene described in humans (Meindl
et al, 2010). However, the biggest limitation of this model was that it did not allow
the study of the tumorigenic potential of the loss of Rad51c alone, because the full
knock-out is embryonic lethal (Kuznetsov et al, 2009). Therefore, the generation
of a conditional mouse model was required (section 4.1).
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1.6 Knock-out mouse models of breast cancer
Several mouse models of breast cancer, especially for genes involved in DNA
repair, such as BRCA1, BRCA2 or PALB, have been created in the past decades, but
the complete knock-out of these genes often resulted in early embryonic lethality,
as mentioned previously (section 1.5). The generation of knock-out animals with a
p53-deficient background has allowed researchers to by-pass this complication.
However, the aggressive nature and short latency of p53-related malignancies has
hampered the study of other tumor types in double knock-out mice. For this
reason, conditional gene knock-outs are now preferred, because they overcome
both embryonic lethality and p53-biased tumorigenesis.
To obtain a conditional knock-out in specific tissues, the Cre-loxP system is
commonly used in combination with tissue specific promoters (Figure 12). Briefly,
the allele of interest (or part of it, i.e. exons or introns) is flanked by loxP
sequences, which are the target of the Cre recombinase, an enzyme that excises
the DNA sequence contained between two loxP sites. When the Cre recombinase
gene is placed under the control of a tissue specific promoter, the loxP-targeted
allele  is  removed  only  in  the  tissue  or  cell  type  that  is  competent  to  drive  gene
expression from that specific promoter, while other tissues remain virtually wild-
type. To study mammary gland
malignancies, a few different
specific promoters are used to drive
expression of the Cre recombinase:
a) whey acidic protein promoter
(WAP), normally driving expression
of the main protein found in rodent
milk, expressed in pregnant and
lactating mammary glands; b)
mouse mammary tumor virus
(MMTV) long terminal repeat (LTR),
Figure 12: Example of tissue specific Cre-loxP
system. From The Jackson Lab.
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active predominantly in mammary epithelial cells; c) β-lactoglobulin gene (BLG)
promoter, which is active in luminal mammary cells; d) Keratin 5 (K5) and Keratin
14 (K14) promoters, both of which drive expression of these keratins in basal
myoepithelial mammary cells. The following table (Table 2) summarises the best-
characterised conditional knock-out mouse models.
Table 2. Selected conditional knock-out models for use in the study of breast cancer.
gene Cre
p53
status
mammary tumors
referencelatency
(months) features
recapitulates
human BC
Trp53f/f WAP-cre - 9.5 ER+; Erbb2 amplification partially Lin et al, 2004
WAP-cre - 9.6 ER+ or - partially Huo et al, 2013
MMTV-
cre
- 10.5 ER+ or -; Erbb2
amplification
partially Lin et al, 2004
K14-cre - 9.6 ER- similar to
sporadic BC
Liu et al, 2007
K14-cre - 10.6 ER+ or - partially Bowman-Colinet al, 2013
Brca1f/f WAP-cre - 17 Triple negative, basal-like yes Shakya et al,2011
WAP-cre Trp53+/- 8.7 Triple negative, basal-like yes Ludwig et al,2001
MMTV-
cre - 16 Basal-like yes
Brodie et al,
2001
MMTV-
cre Trp53
+/- 8 Basal-like yes
Brodie et al,
2001
K14-cre Trp53+/- 8.3 Adenomyoepithelioma partially Molyneux et
al, 2010
K14-cre Trp53f/f 7 Triple negative, high grade,
poorly differentiated
partially Liu et al, 2007
Blg-cre Trp53+/- 11 Triple negative yes Molyneux et
al, 2010
Brca2f/f WAP-cre Trp53+/- 10 Basal-like partially Cheung et al,2004
MMTV-
cre Trp53
+/- 10 Basal-like partially Cheung et al,2004
K14-cre Trp53f/f 6.1 Basal-like, myoepithelial,high grade partially
Jonkers et al,
2001
Blg-cre Trp53f/f 8.3 ER-; high grade yes
Francis et al,
2015
Palb2 f/f WAP-cre - 20 ER+ or -; PR- yes Huo et al, 2013
WAP-cre Trp53f/f 8.2 ER+ or -; PR- yes Huo et al, 2013
K14-cre - 14 ER+ or -; PR- yes Bowman-Colin
et al, 2013
K14-cre Trp53f/f 6.4 ER+ or -; PR- yes Bowman-Colin
et al, 2013
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2 AIMS OF THE STUDY
The aims of this project were to:
· Generate a conditional Rad51c knock-out mouse model of breast cancer
(sections 4.1 and 4.4).
· Study the role of RAD51C in development and differentiation of mammary
and sebaceous glands (sections 4.3 and 4.2).
· Characterize Rad51c-deficient mammary tumors (section 4.4.5).
· Identify mechanisms of Rad51c-mediated tumorigenesis in mammary and
sebaceous cells (section 4.6).
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3 MATERIALS AND METHODS
The materials and methods used in this study are described in detail in the
“Materials and Methods” sections in the original publications and manuscript (I-
III).  Key aspects of the materials and methods used in these publications and
manuscripts are summarized and listed in the following tables:
Table 3:  Experimental procedures performed
Table 4:  Antibodies used in the studies
Table 5: Original source of mouse strains
Table 6:  Details of cell lines and culturing conditions.
Table 3. Experimental procedures performed for publications and manuscript I-III.
method Used in
Mouse genotyping I, II, II
Cryosectioning I
X-gal staining I
Tissue preparation and paraffin sectioning I, II
Immunohistochemistry I, II
TUNEL assay I, II
RNA extraction and cDNA synthesis I, II, III
RT-qPCR I, II, III
Gene expression microarray analysis I
Pathway analysis I
Cell culture I, II, III
Gamma irradiation of cells I, II
Immunocytochemistry I, II, III
SA-β-Gal staining I, II
Gene silencing I, II, III
Genomic DNA isolation and whole genome sequencing II
Copy number variation and mutation analysis II
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Table 4. Antibodies used in publications, manuscript and unpublished experiments.
antibody source Used in
Rabbit anti-Ki67 Abcam I, II
Rabbit anti-γH2Ax Millipore I, II
Rabbit anti-loricrin Abcam I
Rabbit anti-Msh2 Cell Signaling I
Rabbit anti-Keratin 14 Abcam II
Mouse anti-Keratin 18 Abcam II, III
Rabbit anti-ERα Santa Cruz II
Rabbit anti-PR Santa Cruz II
Rabbit anti-Neu Santa Cruz II
Mouse anti-Keratin 7 Abcam unpublished
Rabbit anti-Vimentin Abcam II
Rabbit anti-E-cadherin Cell Signaling II
Rabbit anti-p-Met Cell Signaling II
Rabbit anti-cCasp3 Cell Signaling I, II
Rabbit anti-pericentrin Abcam II
Alexa Fluor 488 phalloidin Molecular Probes II
Goat anti-ΔNp63 Santa Cruz III
Goat anti-TAp63 Santa Cruz III
Mouse anti-Brca1 Calbiochem III
Mouse anti-Nucleophosmin Invitrogen III
Rabbit anti-Mdm2 Abcam III
Mouse anti-p53 Abcam III
Goat anti-mouse Alexa Fluor 488 Molecular Probes I, II
Goat anti-rabbit Alexa Fluor 594 Molecular Probes III
Goat anti-rabbit Alexa Fluor 647 Molecular Probes I, II
Donkey anti-goat Alexa 594 Molecular Probes III
Goat anti Mouse BrightVision poly-HRP ImmunoLogic I, II
Goat anti Rabbit BrightVision poly-HRP ImmunoLogic I, II
Goat anti-mouse IgG H&L (HRP) Abcam I, II
Goat anti-rabbit IgG H&L (HRP) Abcam I, II
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Table 5. Original source of mouse strains used in the study.
strain * targeted allele origin reference
Rad51c neo Rad51c tm1Sks Dr Shyam Sharan, NCI-Frederick,USA
Kuznetsov et al,
2007
Trp53 floxed Trp53 tm1Brn NCI Mouse Repository Jonkers at al, 2001
K14-Cre Krt14 tm1.1(cre)Wbm Dr Irma Thesleff, University ofHelsinki
Huelsken et al,
2001
Brca2 floxed Brca2 tm1Brn NCI Mouse Repository Evers et al, 2008
R26R lacZ Gt(ROSA)26Sortm1Sor
Dr Juha Partanen, University of
Helsinki Soriano et al, 1999
* as referred in the text
Table 6. Cells used in the study and culturing conditions.
cell line description origin culture medium
MCF10A non tumorigenic mammary epithelial,basal human DMEM/F12
MCF10A TP53-/- non tumorigenic mammary epithelial,basal, TP53 knock-out human DMEM/F12
MCF7 breast cancer, luminal human DMEM
SZ95 transformed sebocytes human Sebomed basalmedium
MEFs primary embryonic fibroblasts mouse DMEM
mMECs primary mammary epithelial cells mouse DMEM/F12
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4 RESULTS AND DISCUSSION
4.1 Generation of a conditional knock-out mouse model (I-II)
To overcome the embryonic lethality caused by Rad51c deficiency (Kuznetsov et al,
2009 and section 1.5), we decided to generate a tissue-specific knock-out mouse
that would lack expression of Rad51c only in the organs which were the primary
target of tumors in the DH model (Kuznetsov et al, 2009 and section 1.5). To this
end, we crossed mice with a loxP-flanked Rad51c (sections 1.5 and 3 and Table 5)
and/or Trp53 alleles with a deleter strain expressing the Cre recombinase under the
control of the Keratin 14 promoter (K14cre) (Huelsken et al, 2001). We chose  the
Keratin 14 promoter as it is expressed in basal cells of epidermis, mammary glands
and sebaceous glands (Fuchs et al, 1995), which are all tissues that underwent
tumorigenesis in the DH model (Kuznetsov et al, 2009). After crossing the deleter
strain with the R26R lacZ reporter mice (Soriano et al, 1999), we confirmed that
the K14cre was indeed expressed in the tissues of our interest: basal layer of the
epidermis, mammary epithelial cells and sebaceous glands (I, Suppl. Fig. 1). The
crosses between Rad51c, Trp53 and K14cre strains produced viable offspring that
were indistinguishable at birth from their respective controls (both heterozygous
and wild-type). No animals showed impaired fertility.
The following table (Table 7) summarizes the conditional mouse strains generated
for this study.
Table 7. Conditional mouse strains generated in the study.
Cohort Mutants Controls used in
Rad51c/K14cre Rad51c neo/neo ; K14 cre/+ Rad51c
neo/+ ; K14 cre/+
Rad51c neo/neo ; K14 +/+
I, II
Trp53/K14cre Trp53
lox/lox ; (Rad51c neo/+)
; K14 cre/+ Trp53
lox/lox ; (Rad51c neo/+) ; K14 +/+ I, II
Rad51c/Trp53/K14cre Rad51c
neo/neo ; Trp53 lox/lox
; K14 cre/+
Rad51c neo/neo ; Trp53 lox/lox ; K14 +/+ I, II
Brca2/K14cre Brca2 lox/lox ; K14 cre/+ Brca2
lox/+ ; K14 cre/+
Brca2 lox/lox ; K14 +/+ I
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4.2 Rad51c in development and differentiation of sebaceous
glands
In the DH model, sebaceous glands were a major target for tumors. In fact, while
sebaceous malignancies are extremely rare in p53-knock out animals
(approximately 2%), DH-cis males developed carcinomas in specialized sebaceous
glands with high frequency (section 1.5). The most affected glands were preputial
(42%) and Zymbal’s glands (21%) (Kuznetsov et al, 2009). Preputial glands are large,
symmetrical sebaceous glands associated with the male reproductive system and
they are best known for producing, in rodents and few other species,
pheromones. Females have similar but smaller organs, called clitoral glands.
Zymbal’s glands are found in the ear canal of both sexes. In general, specialized
sebaceous glands, as well as those associated with the hair follicle in the epidermis,
are composed of
sebocytes, epithelial
cells that are
specialized in the
production of
sebum, an oily
substance important
for maintaining the
skin lubricated and water-proof, as well as acting as anti-bacterial (Thody and
Shuster, 1989). Sebocytes differentiate from a common keratinocyte/sebocyte
precursor, and once mature, they release their product by holocrine secretion
(Figure 13) (Niemann et al, 2012).
Figure 13: Schematic representation of (hair follicle-
associated) sebaceous gland. Modified from Niemann, 2012.
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4.2.1 Deletion of Rad51c in mouse sebaceous glands induces apoptosis
and transdifferentiation (I and unpublished)
We first focused on analysis of preputial glands, as they were the most affected
organs in the DH model. We collected glands from five week, two month, and four
month old Rad51c/K14cre mutant and control mice. We also collected testes,
because in the hypomorphic model these were significantly smaller than in wild-
type animals (Kuznetsov et al, 2007), but we did not find a difference in testis
weight in mutants when compared with control males (Figure 14). However,
histological analysis of preputial glands revealed a depletion of mature follicles in
mutant tissues, detectable by two months of age. At the same time, we found
ectopic keratinization of the collecting ducts, as revealed by loricrin, a marker for
terminally differentiated keratinocytes, staining (Hu et al, 2012). Moreover, mutant
glands were characterized by impaired cellular proliferation and a significant
increase in apoptosis,
when compared to
control glands.
However, Rad51c-
mutant preputial
sebocytes failed to
show signs of
unrepaired DNA
damage, as assessed
by γH2Ax staining (I,
Fig. 3).
We hypothesise that these phenotypes are all caused by the deleterious
loss of Rad51c and consequent activation of cellular checkpoints and p53. The
tumor suppressor p53 and its isoforms control a variety of cellular processes, such
as cell cycle checkpoints, proliferation, apoptosis, differentiation and senescence.
First,  p53  has  been  shown  to  be  involved  in  both  G1  and  G2/M  arrest,  through
Figure 14: Weight of mutant and control preputial glands and
testes for the indicated age groups. Weight is calculated as
percentage on total body mass (unpublished).
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induction of CDK inhibitors, such as p21/Cdkna1/Cip1 or 14-3-3σ (Olivares-Illana and
Fåhraeus, 2010), leading to stalled proliferation. Second, p53 activation has been
reported to be responsible for initiation of apoptosis, through induction of PUMA
(P53 up-regulated modulator of apoptosis) and other pro-apoptotic proteins that
are direct targets of p53 (Fujita et al, 2009). Last, p53-mediated expression of p21
during G1 has been shown to be sufficient to induce both cellular differentiation
and senescence, as alternatives to apoptosis (Zhu et al, 2001; Fujita et al, 2009).
Therefore, in Rad51c-deficient preputial glands, similar to Rad51c knock-out
embryos, p53 activation is likely to lead to both halted proliferation and increased
apoptosis.
The fact that mutant sebocytes are virtually devoid of DNA damage
suggests that lack of RAD51C is detrimental for such cells and causes their growth
arrest and immediate elimination via apoptosis. As a result, such cells cannot be
detected in vivo. However, the presence of ectopic keratinization also suggests
that mutant progenitors can potentially exit the cell cycle by undergoing
transdifferentiation into keratinocytes, since keratinocytes and sebocytes derive
from the same multipotent cell (Niemann et al, 2012). While this mechanism has
been described for other epithelial progenitor cells, this hypothesis requires
further investigation in sebaceous cells.
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4.2.2 Defects in the homologous recombination pathway do not
recapitulate the Rad51c-deficient phenotype in preputial glands
(unpublished)
Knock-out of different components of the HR pathway causes similar effects in
mouse embryos and cells and predisposes the animals to specific cancers (Suwaki
and Tarsounas, 2011). For this reason, we asked whether defects in HR cause the
phenotype described in Rad51c-deficient preputial glands, and we sought to
answer this question by analysing another knock-out mouse model:  the Brca2
knockout mouse model.
We chose BRCA2 as representative of the HR pathway for the two
following reasons. First, BRCA2 is a key player in the DSB repair pathway and linked
Figure 15: A. schematic representation of Brca2 conditional and knock-out allele after
Cre-mediated recombination. B-G. Morphological features of Brca2/K14cre and control
glands. Ki67, proliferation marker; TUNEL, apoptotic marker; γH2Ax, DNA damage
and Lor, keratinization. L. Quantification of expressions shown in D-I.  (unpublished)
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to cancer predisposition in different tissues (San Filippo et al, 2008; Jasin et al,
2002). Second, several knock-out mouse models of Brca2 have already been
generated and used extensively to study its role in mammary development and
tumorigenesis (Jonkers et al, 2001; McAllister et al, 2002; Cheung et al, 2004; Evers
et al, 2008; Francis et al, 2010; Francis et al, 2015). However, the focus on mammary
glands has led to biased results, with virtually no data on other tissues reported.
To address this concern, we generated cohorts of conditional knock-out
males by crossing a Brca2 floxed strain (Evers et al,  2008) with the same K14cre
deleter mouse strain used for establishing the Rad51c/K14cre study cohort (section
4.1). We collected preputial glands from two- and four month old Brca2/K14cre
mutant mice and their controls and analysed them immunohistochemically for
cellular proliferation, presence of DNA damage or apoptosis and keratinization
(Figure 15). Notably, Brca2-deficient preputial glands failed to recapitulate the
features of Rad51c mutants. In fact, while glands from two month-old males
revealed higher levels of apoptosis and DNA damage, the same values dropped in
tissues from four month-old animals compared to those of the control males.
Furthermore, we did not detect any effect on proliferation, and most strikingly,
glands from Brca2/K14cre mice were completely devoid of loricrin, indicating that
lack of Brca2 in preputial sebocytes does not cause their transdifferentiation into
keratinocytes.
 Based on these studies, we concluded that defects in HR are likely not the
cause of the phenotype we described in Rad51c/K14cre males (section 4.2.1), and
that RAD51C plays an additional role in preputial sebocytes, independent from its
recombinational functions.
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4.2.3 Gene expression changes in Rad51c-deficient preputial glands (I)
In order to identify potentially HR-independent functions of RAD51C, in addition to
a possible role in keratinization revealed by immunohistochemistry, we decided to
adopt a gene expression approach. To this end, total RNA from preputial glands
of two month-old and four month-old Rad51c/K14cre mutant and control mice was
used for microarray analysis with the Affymetrix Mouse Gene 1.0 ST chip
(Affymetrix, Santa Clara, CA, USA). After quality control was performed using
hierarchical clustering with Ward’s linkage and Spearman correlation, unpaired t-
test and two-way ANOVA were applied for detection of significantly differentially
expressed genes. Subsequently, both an Ingenuity Pathway Analysis (IPA) and a
Gene Set Enrichment Analysis (GSEA) were performed between experimental and
control groups, as well as between different experimental groups, using a cut-off
value of 0.05.
Although the high heterogeneity found between mice of the same age and
genotype group did not permit us to pinpoint individual genes that were
significantly differentially expressed, we were able to identify a few pathways that
were consistently de-regulated in Rad51c/K14cre mutant  preputial  glands.   In
particular, several genes encoding for pro-apoptotic proteins were up-regulated,
while genes responsible for cellular proliferation were generally down-regulated
(I,  Suppl.  Fig.  2),  consistent  with  our  immunohistochemical  findings  (I,  Fig.  3).
Rad51c mutant preputial glands were also characterized by a sharp up-regulation
of loricrin and other genes which are normally expressed in keratinocytes, such as
involucrin and filaggrin, while genes encoding key enzymes for the synthesis of
lipids were generally down-regulated (I, Suppl. Fig. 2). This last finding suggested
that RAD51C might, indeed, have a role in the differentiation and maintenance of
sebocytes, although the mechanisms are still partially unclear.
Based on both immunohistochemistry (I, Fig. 3) and gene expression
analysis (I, Suppl. Fig. 2), we hypothesise that RAD51C is required for the proper
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development and function of preputial sebocytes. We suggest that loss of RAD51C
at the level of basaloid cells suppresses the sebaceous differentiation of precursor
cells and leads to a switch towards the keratinocyte lineage, while its loss in cells
already committed to become sebocytes triggers apoptosis. We conclude that the
combination of transdifferentiation, apoptosis and decreased proliferation caused
by the loss of RAD51C results therefore in depletion of mature sebaceous cells.
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4.2.4 Deletion of RAD51C in human sebaceous cells (unpublished)
Although Homo sapiens does not possess preputial glands, tumors of sebaceous
origin are found in humans as well, similar to mice. Sebaceous neoplasms in
humans are rare but aggressive tumors, occurring mostly in the periocular region
and often associated with Lynch and Muir-Torre syndromes, which are caused by
defects in mismatch repair (Lynch et al, 1993; Ponti et al, 2005).
To rule out if RAD51C is required for development and maintenance of
sebaceous glands in humans, we decided to investigate the effect of RAD51C loss
in human sebaceous cells using the immortalized sebocyte line SZ95 (Zouboulis et
al. 1999). Using RNA-interference, we knocked-down the expression of RAD51C
and then treated the cells  with arachidonic acid (AA),  which induces full  cellular
maturation and production of lipids and sebum. As expected, treatment of control
Figure 16: Depletion of RAD51C in human sebocytes causes overproduction of  lipid
droplets (Nile Red, C-D) and expression of the keratinocyte marker loricrin (G-H), at
the expense of the sebocyte-specific keratin (Krt) 7 (K-L). A, E, I, C, G and K represent
untreated cells, while B, F, J, D, H and L represent cells treated with 100µM arachidonic
acid  (AA)  to  induce  sebocyte  differentiation.  Scale  bars  correspond  to  50µm.
(unpublished)
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SZ95 cells with AA induced the expression of the sebocyte-specific keratin (Krt) 7
(Figure 16 J) and accumulation of lipid droplets in the cytoplasm, revealed by Nile
Red staining (Figure 16 B). However, depletion of RAD51C induced a stronger
production of lipid droplets even without treatment with AA (Figure 16 C-D).  At
the same time, RAD51C-depleted cells expressed low levels of the sebocyte-
specific Krt7 (Figure 16 K-L), but high levels of loricrin (Figure 16 G-H), similar to
Rad51c-mutant preputial glands (I, Fig. 3).
Although loss of Rad51c in mice does not lead to tumor formation and
despite the lack of evidence that RAD51C is  linked  to  sebaceous  malignancies  in
humans, we did observe phenotypic resemblances between mouse preputial
tissues  and  SZ95  cells.  First,  loss  of  RAD51C  leads,  both  in  mouse  and  human
sebocytes, to ectopic expression of loricrin, an indicator of terminal differentiation
and exit from the cell cycle. Second, RAD51C-deficiency causes a depletion of
mature preputial sebocytes in vivo and, similarly, a decrease in Krt 7-positive SZ95
cells. Thus, we hypothesized that RAD51C may play a similar role in both mouse
and human sebaceous cells.
However, although sebaceous carcinomas in humans have high rates of
recurrence and metastasis and mortality rates ranging from 9% to 50% if untreated,
such neoplasms are usually easily diagnosed and removed surgically before
becoming invasive (Eisen et al, 2009). To the contrary, breast cancer remains one
of the leading causes of death among women. Thus, we decided to focus our
studies on the role of RAD51C in mammary tumorigenesis, rather than sebaceous
carcinomas.
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4.3 RAD51C in the development of mouse mammary glands
(unpublished)
The development of mammary glands starts already during early stages of
embryonic life when secretion of FGF10 (Fibroblast growth factor 10) from the
developing somites triggers the release of WNT ligands, leading to inhibition of
SHH (Sonic Hedgehog) and subsequent formation of the primitive mammary line,
instead of the default pilosebaceous unit (Chu et al, 2004; Veltmaat et al, 2006).
After the appearance of the mammary line, distinct mammary placodes develop
as a result of crosstalk between the epithelium and the underlying mesenchyme.
Such crosstalk leads to the release of morphogens such as BMPs (Bone
Morphogenetic Proteins), which are essential for the invasion of the epithelium into
the mammary fat pad and formation of the rudimentary mammary tree (Mikkola
et al, 2006). Later on, the development of the mammary gland is controlled by
growth factors and hormones, especially estrogen and progesterone (Howlin et
al, 2006). Starting from pubertal age, the mammary gland undergoes rounds of
proliferation (ductal elongation and branching) and cell death as a result of the
oestrus cycles. During gestation, the mammary gland is subject both to a sustained
ductal and alveolar proliferation, as well as alveolar differentiation and maturation
of epithelial luminal cells, responsible for the production of milk (Brisken et al,
1999). When lactation ceases, the mammary glands returns to its pre-gestational
stage in a process called involution, which consists of cellular apoptosis and tissue
remodelling (Alexander et al, 2001; Lund et al, 1996; Watson et al, 2006).
Since each step of the development of mammary glands is tightly
controlled by morphogens, hormones and remodelling factors, perturbation of
any of these players results in defects and aberrations of gland morphology and/or
function (Mikkola et al, 2006). In addition, defects in other proteins playing a role
in mammary gland maintenance also lead to an aberrant phenotype. For example,
female mice with a conditional mutation in Brca1 are characterized by defective
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alveolar development, especially during pregnancy, and a higher rate of glandular
apoptosis after parturition, resulting in a faster involution than in wild-type
females. Nevertheless, Brca1-mutant females are able to lactate and nurse their
offspring  (Xu  et  al,  1999).  Reduced  ductal  elongation  and  branching  is  also
described in a transgenic mouse carrying a truncating mutation of Brca2
(McAllister et al, 2002), while a conditional Brca2-mutant does not reveal
abnormalities in development or involution of the mammary gland (Cheung et al,
2004).
Since there are some indications that genes linked to breast cancer
predisposition may also play a role in mammary development, we decided to
investigate whether loss of Rad51c also leads to glandular defects. To this end, we
collected  the  fourth  inguinal  mammary  glands  from  two  and  four  month-old
Rad51c-mutant virgin females and examined the branching and elongation
morphology by whole mount staining with Carmine Alum, a technique that allows
visualization of the whole mammary tree (Figure 17). We found that mammary
glands from Rad51c/K14cre mutant virgin females (Figure 17 B, F) were completely
comparable to wild-type females (Figure 17 A, E), regardless of the oestrus cycle
phase. In addition, Rad51c-mutant mammary glands from 16 dpc females, as well
Figure 17: Carmine Alum-stained mammary gland whole mounts from 2 and 4 months-
old females of the indicated genotype. (B, F) Loss of Rad51c does not impair
elongation and branching. (D, H) Loss of Trp53 causes increased side branching, which
is exacerbated in Rad51c/p53 double mutant females (C G). The arrow in G indicates a
small DCIS.  (unpublished)
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as glands from involution day 5, were indistinguishable from control glands,
suggesting that RAD51C is not essential for mammary gland development and
differentiation.
4.4 Rad51c acts synergistically with Trp53 to induce
tumorigenesis (I-II)
To determine whether the loss of Rad51c alone can drive tumor progression, we
monitored a cohort of Rad51c/K14cre mutant females and males, together with a
control cohort, for up to 18 months for tumorigenesis. We found that both females
and males appeared phenotypically normal and indistinguishable from their age-
matched controls, although mutant males occasionally possessed a “greasy” coat,
which is likely a result of imbalance in sebum production by their hair follicle-
associated sebaceous glands. Most remarkably, Rad51c/K14cre mutant mice failed
to  produce  any  tumors,  even  after  18  months,  demonstrating  that  deletion  of
Rad51c alone is not sufficient to promote tumorigenesis.
Since Trp53 plays a role in the phenotype characterising the Rad51c/K14cre
preputial glands and is responsible for the embryonic lethality associated with
Rad51c knock-out mice, we decided to investigate the relationship of Trp53 with
Rad51c in our conditional mouse model. To this end, we generated a conditional
double mutant knock-out by crossing Rad51c/K14cre mice with a strain carrying a
Trp53-floxed allele (Jonkers at al, 2001). We used mice with genotype Rad51c neo/neo;
Trp53 lox/lox; K14 cre/+ (called Rad51c/p53/K14cre) as mutants and littermates without
Cre as controls. In parallel, we also generated a conditional p53 single knock-out
cohort (and their littermates without Cre) as the positive control model for
tumorigenesis. p53/K14cre knock-out mice were already reported to be susceptible
to  mammary  and  skin  tumors  in  different  studies  (Jonkers  at  al,  2001;  Liu  et  al,
2007; Krimpenfort et al, 2012).
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As expected, p53/K14cre mice  developed  tumors  with  a  latency  of
approximately  11  months  and  a  penetrance  of  81%  for  females  and  only  16%  for
males. Rad51c/p53/K14cre mutant mice developed tumors, as well. However, their
tumor-free survival was dramatically shortened to about six months (I Fig. 1A; II
Fig. 1A). In addition, Rad51c/p53/K14cre mice  developed  tumors  with  full
penetrance, and both females and males suffered from multiple neoplasms (>2
tumors/animal), while p53/K14cre mice succumbed mostly to a single tumor.
While there were no significant differences in tumor latency between DH
mice and Trp53 knock-outs  (Kuznetsov  et  al,  2009),  we  proposed  that  the
acceleration in tumor formation characteristic of the Rad51c/p53/K14cre mice can
be explained by the nature of the model itself: in Rad51c/p53/K14cre animals, the
Cre-mediated deletion of Rad51c and Trp53 is a stochastic event that takes place
already during embryonic life, when the Keratin 14 promoter becomes active. In
the DH model, and particularly in the DH-cis genotype, deletion of Rad51c is
dependent on LOH of Trp53, an event that occurs in late stages of tumorigenesis
(Bowman et al, 1996; Rivlin et al, 2011).
On the other hand, our data show that inactivation of Trp53 is required for
Rad51c-mediated carcinogenesis but, at the same time, loss of Rad51c accelerates
tumor development of Trp53-deficient animals. These results are a clear indication
of synergistic activity of the two genes. Such a finding is not surprising, given that
a similar synergy has been described in a number of studies of other genes linked
to cancer, such as the cooperation observed i. between Trp53 and Kras in  lung
carcinomas (Caulin et al, 2007); ii. among the breast cancer susceptibility genes
Brca1, Brca2 and Palb2 (Liu et al, 2007; Jonkers et al, 2001; Bowman-Colin et al,
2013); or iii. with Cdh1 in invasive lobular carcinoma of the mammary gland
(Derksen et al, 2006). In general, independent of the tissue or the promoter used
to induce excision of targeted alleles, the concomitant deletion of another tumor
suppressor is commonly able to accelerate tumorigenesis in a Trp53-deficient
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background. In this regard, we conclude that Rad51c is a tumor suppressor and
that it synergises with Trp53 to prevent tumorigenesis.
4.4.1 Loss of Rad51c promotes epithelial tumorigenesis in Trp53-mutant
mice (I-II)
The increase in epithelial-derived tumors reported in DH mice was the first
indication that Rad51c acts as a tumor suppressor in specific tissues (Kuznetsov et
al, 2009). Accordingly, we found a marked increase in epithelial-derived tumors in
Rad51c/p53/K14cre mice when compared to p53/K14cre animals (Table 8).
Table 8. Tumor spectra, incidences and % of total tumors in Rad51c- and Trp53-mutant mice.
Tissue Tumor (%)
Rad51c/p53/K14cre p53/K14cre
females
n=38
males
n=34
females
n=27
males
n=19
Skin SCC 54 71 19 6
Mammary gland carcinoma 63 3 70 -
Preputial/clitoral gland SCC 8 77 7 5
Zymbal’s gland SCC 32 23 7 -
Meibomian gland SCC 5 15 - -
Muscle sarcoma - - 7 -
Muzzle area SCC 19 9 4 -
Skin cysts 24 30 7 5
Prevalence (%) 100 100 81 16
Number of tumors/animal (average) 2.7 2.23 1.3 0.16
Tumor-free survival (average) 5,8 months 5,8months
10,9
months
10,4
months
By using K14-driven expression of the Cre recombinase, we essentially focused on
skin and ectodermal-derived glands, although the resulting tumor spectrum was
still heavily affected by the status of Rad51c.  In fact,  54-70% of Rad51c/p53/K14cre
animals developed multiple skin carcinomas, while the same tumors were present
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in  less  than  20%  of p53/K14cre mice. Moreover, carcinomas of specialized
sebaceous glands such as preputial, Zymbal’s and Meibomian glands, virtually
affected only Rad51c/p53/K14cre animals, consistent with the tumor spectrum
reported for the DH mice.
In contrast to the DH model, the incidence of mammary gland carcinomas
in Rad51c/p53 and p53 mutant  females  was  nearly  identical  (63%  and  70%,
respectively). However, mammary tumors in Rad51c/p53/K14cre females develop
earlier, as early as four months of age, and grow larger in a short time, consistent
with a tumor suppressor role of RAD51C.
4.4.2 Rad51c/p53 double mutant mouse tissues develop early in situ
carcinomas (I-II)
Cancer is a progressive disease that starts with malignant transformation of a
single cell which acquires growth advantage and proliferates faster than
neighbouring normal cells, until it eventually gives rise to a small, localized, and
non-invasive tumor mass, called in situ carcinoma. Although there is disagreement
whether in situ carcinomas are to be considered already tumors or simply
dysplastic tissue, there is no doubt that such lesions can progress into full-blown
carcinomas, which are more aggressive and can invade surrounding tissues and
enter the blood stream to metastasize to secondary locations. Therefore,
detection of in situ carcinoma and its removal, whether surgical or chemo-radio
therapeutic, are essential to prevent or drastically reduce the life-threatening
complications of an invasive tumor.
As previously mentioned, the tumor-free survival of Rad51c/p53/K14cre
mice is about six months of age, although several animals developed tumors as
early as four months of age. To determine when the first signs of tumorigenesis
appear in double mutant tissues, we collected mammary and preputial glands
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from two and four month-old Rad51c/p53/K14cre males and females, as well as
glands from age-matched p53/K14cre mutants, and analysed them histologically (I,
Fig. 2 and II, Fig. 2).
We found that mammary glands from two month-old double mutant
females appeared normal, but approximately 30% of four month-old
Rad51c/p53/K14cre animals presented lesions comparable to human ductal
carcinomas in situ (DCIS), which, in mice, are classified as mammary intraepithelial
neoplasias (MINs) (II, Fig. 2G and I). On the other hand, such lesions are not found
in age-matched p53/K14cre females, consistent with the longer tumor-free survival
of p53-mutant animals. At the same time, we also found that 70% of
Rad51c/p53/K14cre females that were sacrificed due to macroscopic tumors in other
organs had multiple MINs in their macroscopically normal mammary glands, while
only 30% of such lesions were found in p53/K14cre females (II, Table 1).
Similarly, in situ carcinomas were readily observed in about 70% of
preputial glands from four month-old Rad51c/p53/K14cre males, but not in age-
matched p53/K14cre mice (I, Fig. 2A and B). In addition, nearly all preputial glands
from double mutant mice showed multiple areas of hyperplasia already at two
months of age, while only 20% of p53-mutant males presented the same phenotype
(I, Suppl. Table S3). When we analysed these lesions more closely in four month-
old animals using immunohistochemistry, we found a 2.0-2.5 fold increase in
cellular proliferation in double mutant preputial glands, together with an increase
in DNA damage (I, Fig. 3B and L).  Furthermore, apoptosis was lower than in age-
matched control glands (I, Fig. 3G and F).  On the other hand, p53/K14cre preputial
glands were similarly characterized by low levels of apoptosis and sustained DNA
damage, but cellular proliferation did not reach the same magnitude as in double
mutants (I, Fig. 3E). The other major difference between the two genotypes was
the staining pattern of proliferation and DNA damage markers. In
Rad51c/p53/K14cre glands, such markers were expressed in a mosaic pattern with
some follicles almost entirely positive, while others remained rather devoid of
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expression (I, Fig. 3B and L). Within a positive follicle, DNA damage appeared to
more severely affect sebocytes of the basal layer, which is the cellular
compartment that normally proliferates in wild-type glands. However,
proliferating cells were found also in suprabasal layers in double mutant glands,
indicating a loss of glandular organization or expansion of progenitor cells with
DNA damage (I, Fig. 3B, arrowheads). In this regard, the mosaic phenotype can be
explained by the independent synchronization of each follicle, which develops
from a limited number of progenitor cells: since the Cre-mediated excision of
Rad51c and Trp53 is a stochastic event, deletion (or not) of the targeted alleles in a
specific basal cell of a particular follicle, results in a progeny with the same
sebocyte phenotype, hence the mosaic pattern that characterizes double mutant
glands. Furthermore, we suggest that the abnormal follicles are the ones that
actually progress into in situ carcinomas and, subsequently, into full-blown tumors.
4.4.3 Squamous carcinomas (I-II)
Squamous cell carcinoma (SCC) is a highly invasive malignancy that often forms
metastases  and affects organs and tissues covered by a squamous epithelium,
such as the epidermis, oral mucosa, oesophagus and fore stomach, lungs, urinary
tract, prostate, cervix and vagina (Yan et al, 2011). Cutaneous SCC is the second
most common malignancy of the skin, after basal cell carcinoma, and represents
20% of non-melanoma skin cancers. It occurs mostly in sun-exposed areas of the
body; in fact, 90% of cutaneous SCC arises as head and neck cancers (HNC).
While there are environmental risk factors, such as exposure to solar UV
radiation, tobacco smoke, alcohol consumption and infection by papilloma viruses,
for the development of SCC, a portion of these neoplasms also have a genetic
cause. Among others, mutations in genes such as PTEN, KRAS, EGFR and P16INK4A
are  often  found  in  SCC,  and  there  is  evidence  that  genetic  variants  of RAD51C
modulate the risk of head and neck SCC (HNSCC) (Gresner et al, 2014).
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Accordingly, we found that squamous carcinomas were the most common
type of malignancy developed by Rad51c/p53/K14cre mice, both females and males.
When considering only cancers originating in the epidermis, 55 to 70% of all tumors
isolated from double mutant mice were SCCs of the skin, while the same
accounted for less than 20% in p53/K14cre animals  (Table  8).  In  addition,  double
mutant  mice  developed  up  to  20%  of  SCC  in  the  muzzle  area,  including  tumors
originating from the nasal and oral mucosa, which are similar to human HNSCC
(Table 8).
A similar incidence of skin-derived SCC has been described in other mouse
models of HR-related cancers. For example, a conditional Brca1/p53/K14cre model
was reported to develop skin tumors in addition to mammary carcinomas (Liu et
al, 2007), while another skin-specific Brca1 single knock-out reveals that mutant
progenitor cells in the hair follicle accumulate DNA damage and undergo p53-
induced apoptosis, resulting in a depletion of progenitors and a progressive loss
of hair follicles. However, loss of BRCA1 does not affect the interfollicular
epidermis or sebaceous glands (Sotiropoulou et al, 2013). Brca2/p53/K14cre females
also develop SCC of the skin or hair follicle and carcinomas of the jaw with an
epidermal origin (Jonkers et al, 2001). Furthermore, 11% of Palb2/p53/K14cre mutant
females develop tumors of the skin and oral mucosa, in addition to mammary
carcinomas, and 50% of tumors classified generally as “epithelial” (Bowman-Colin
et al, 2013). Taken together, these studies show that there is clear evidence for a
requirement for genes involved in recombinational repair in the maintenance of
epidermal cells and prevention of skin tumorigenesis.
4.4.4 Sebaceous carcinomas (I)
Most sebaceous malignancies in humans arise in patients affected by Lynch and
Muir-Torre syndromes, both of which are caused by mutations in genes, such as
MSH2, MLH1 and MSH6, involved in the DNA mismatch repair (MMR) pathway
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(Lynch et al, 1993; Ponti et al, 2005). These sebaceous tumors are usually
characterized by microsatellite instability (MSI) as a direct effect of defective
MMR, which is normally required for the maintenance of highly repetitive genomic
regions, such as microsatellites (Santillan et al, 2011; Bhaijee et al, 2014).
To  rule  out  any  involvement  of  MMR  genes  in  the  development  of
sebaceous tumors in Rad51c/p53/K14cre mice,  we  detected  MSH2  protein  in
preputial samples by immunohistochemical staining. We found that MSH2 was
expressed in normal glands by proliferating sebocytes located at the periphery of
each follicle, adjacent to the basal membrane (I, Fig. 4A). In hyperplastic areas of
the gland, in both Rad51c/p53/K14cre and p53/K14cre mutants, the population of
MSH2-expressing cells was expanded to suprabasal sebocytes and overlapped
with the population of Ki67-positive cells, suggesting that overexpression of MSH2
can be considered an index of active proliferation, rather than the cause of
tumorigenesis. Such a mechanism has been proposed for other normal tissues and
tumors,  such  as  normal  peripheral  blood  lymphocytes  (Iwanaga  et  al,  2004),
melanoma cells (Rass et al, 2001), salivary gland cancers (Castrilli et al, 2002), and
glioblastoma (Srivastava et al, 2004). In fact, consistent with this hypothesis, MSH2
expression decreased in areas of squamous differentiation in Rad51c/p53/K14cre
preputial carcinomas, which correspond to non-proliferating portions of the
tumor  (I, Fig. 4C and G). The reason for such overexpression of MSH2 in
proliferating cells is not completely clear, but one explanation is that actively
cycling cells introduce mismatches more frequently as a direct effect of an increase
in DNA replication (Seifert et al, 2006). Of note, MSH2 was also overexpressed in
sebaceous tumors isolated from the DH mice, where its staining pattern was
extended to suprabasal sebocytes, clearly suggesting that expression of MSH2 is
not linked to loss of RAD51C.
On the other hand, the high incidence of tumors of sebaceous origin in
Rad51c/p53/K14cre mice indicates that Rad51c, but not Trp53, plays a unique role in
sebocytes. Based on our findings in single mutant preputial glands, we previously
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concluded that loss of Rad51c triggers: i. a p53-induced transdifferentiation
towards keratinocytes in basaloid precursors; and ii. p53-mediated apoptosis in
differentiating sebocytes. However, only a concomitant deletion of Trp53 allowed
Rad51c-deficient sebocytes to proliferate and give rise to tumors. Interestingly,
even when Trp53 was lost, keratinization remained a characteristic of Rad51c-
mutant preputial tumors, confirming that RAD51C is required for sebaceous
differentiation.
4.4.5 Mammary carcinomas (II)
One  of  our  main  goals  was  to  generate  a  transgenic  mouse  model  that  would
spontaneously develop mammary carcinomas, allowing us to better understand
why inactivation of RAD51C in humans is a predisposition to breast cancer. In this
study,  63%  of Rad51c/p53/K14cre females developed mammary carcinomas and,
among the p53/K14cre mutants, the percentage reached 70% (II, Table 1). While at
first it might appear like there was no difference between the two cohorts in terms
of tumor incidence, it must be pointed out that double mutant females developed
multiple carcinomas, and with a shorter latency than p53-mutants (II, Fig, 1A).
Accordingly, we found presence of MINs in 70% of macroscopically normal
mammary glands isolated from double mutant females that succumbed to other
malignancies (section 4.4.2), which was an indication that Rad51c/p53/K14cre mice
have a higher potential for mammary tumorigenesis. However, the fast
development of other tumors (e.g. skin SCC) precludes the progression on MINs
into full-blown carcinomas. A similar phenomenon was seen in other transgenic
models of breast tumors. For example, a study of a Palb2 model reported that 50%
of mutant Palb2/p53/K14cre females developed mammary tumors, compared to
88% of the corresponding p53-mutants. However, the tumor-free survival of
Palb2/p53/K14cre females was also shorter than that of the p53 knock-outs
(Bowman-Colin  et  al,  2013).  On  the  contrary,  compound  mutants  of Trp53 and
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Brca1/Brca2 have a slightly increased incidence of mammary tumors than their
corresponding p53-mutants: from 63% to 78% for Brca1 (Liu et al, 2007) and 55% to
71% for Brca2 (Jonkers et al, 2001).
The main difference between Rad51c/p53/K14cre and p53/K14cre
mammary tumors was revealed by their histological classification. While most p53-
mutant females developed poorly differentiated solid carcinomas (64%; II, Table 1
and Fig. 1), double mutant tumors were mainly represented by adenosquamous
carcinomas and moderately differentiated solid carcinomas (29% and 24%,
respectively; II, Table 1 and Fig. 1). Interestingly, this distinction was also reflected
in histological features of the MINs found in macroscopically normal mammary
glands (II, Table 1). In addition, Rad51c/p53/K14cre solid carcinomas were better
vascularized and lacked the extensive necrosis that characterised p53-mutant
tumors (II, Table 1 and Fig. 1), suggesting that double mutant tumors might grow
faster and larger as a result of increased angiogenesis.
4.4.5.1 Genomic signature of Rad51c mammary tumors (II)
The specific combination of mutations, insertions and deletions that characterizes
a tumor is known as its “genomic signature”. In the case of breast cancer, whole
genome sequencing has revealed that tumors cluster into more subgroups than
known previously based on immunohistochemical profiling (Curtis et al, 2012).
Undoubtedly, better identification of a cancer subtype can be highly beneficial in
the choice of treatment; therefore, the genomic signature plays an important,
complementary role.
Genome sequencing of mouse tumors has also helped to find recurrent
mutations and aberrations caused by breast cancer susceptibility genes, such as
Brca1, Brca2 and Palb2 (Zvelebil et al, 2013; Francis et al, 2015; Bowman-Colin et al,
2013).  Furthermore, genomic data has been used to identify differences and
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similarities between human breast cancers and their murine counterparts. For
example, an effort to directly compare human and mouse mammary tumor
signatures was made for BRCA1 and BRCA2, revealing that some aberrations are
present across species, while other are found specifically in either species
(Holstege et al, 2010).  Importantly, since our study described the first mouse
model of RAD51C-associated breast cancer, we decided to characterize the specific
genomic signature of Rad51c/p53/K14cre tumors, to test for the presence of
recurrent aberrations and compare them to other known models.
To this end, we performed exome and low-coverage full genome
sequencing for three Rad51c/p53/K14cre and four p53/K14cre mammary tumors. We
compared the tumors with isogenic genomic DNA isolated from livers of the same
mice. By using liver, a tissue not subject to Cre-mediated gene deletion, as
reference tissue, we were able to identify and validate a few somatic mutations in
five of the seven original mammary tumors (II, Suppl. Fig. 3). Although none of the
samples revealed recurrent mutations, we noticed that Rad51c/p53/K14cre tumors
were characterized mainly by large-scale chromosomal amplifications and
deletions, while p53/K14cre samples presented a higher frequency of small (1-25
nucleotides) insertions and deletions. The gross chromosomal aberrations found
in double mutant tumors suggest that loss of Rad51c triggers widespread genomic
instability. However, analysis of copy number variation (CNV) in Rad51c/p53/K14cre
mammary tumors revealed few differences when compared to the signature of
p53/K14cre samples. Among the differences, we observed a weak tendency for
deletion of the pro-apoptotic gene Casp3 and amplification of the hormone
receptor genes Esr1 and Prg (II, Suppl. Fig. 3). Despite the tumor allele frequency
for these loci deviated only up to 1.5 fold from control samples, we observed the
exact opposite behaviour in p53/K14cre tumors, indicating that mammary tumors
from Rad51c or p53 mutant females have a different genomic signature. In support
of this observation, we found a recurrent amplification at chromosome 6 in three
out of the four p53-mutant tumors, but not in Rad51c double mutant tumors (II,
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Fig.  3B).  This  amplified  segment  contains  the  gene  encoding  for  the  receptor
tyrosine kinase Met (Met proto-oncogene tyrosine kinase), a target for the
hepatocyte growth factor (HGF). Met is  known  to  be  amplified  in  up  to  70%  of
Trp53-mutant mouse models (Smolen et al, 2006; Bowman-Colin et al, 2013; Knight
et al, 2013) and approximately 20% of human TP53-mutated human breast cancers
(Parr et al, 2004; Ho-Yen et al, 2005). Met expression is associated with the
development of a spindloid phenotype and epithelial-to-mesenchymal transition
(EMT) (Lee et al, 2006).
Despite the small sample size used in this study precluded the
identification of recurring mutations in double mutant mammary tumors, the
presence of gross chromosomal aberrations and the absence focal amplifications
and deletions, such as Met, indicates that loss of Rad51c causes genomic instability,
which is essentially the main driver of tumorigenesis.
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4.4.5.2 Rad51c-deficient mouse mammary tumors resemble RAD51C-
mutated human breast cancers (II)
A recent and extensive clinicopathological study of breast and ovarian cancer
patients with RAD51C germ-line mutations reported that RAD51C-mutant mammary
tumors are epithelial-like, hormone receptor-positive, and HER2-negative invasive
carcinomas of no special type, diagnosed mainly at an early stage (Gevensleben et
al,  2014).  Among  patients  with  deleterious  mutations  in RAD51C,  almost  70%  of
mammary tumors were represented by moderately differentiated carcinomas,
and only two cases were classified as basal-like breast cancers.  However, in
RAD51C mutation carriers of unclassified variants (UCVs), 60% of tumors were
poorly differentiated. The study also reported high expression of cytokeratin 18,
but a low proliferation index (Ki67 < 20%), suggesting that RAD51C-related breast
cancers may belong to the “luminal A” subtype, which has a more favourable
prognosis than basal-like triple-negative (e.g. BRCA1-mutated) and “luminal B”
breast cancers (e.g. BRCA2-mutated).
In addition to the classification of mammary tumors based on proliferative
index, the study also showed that RAD51C-mutated breast cancers were highly
positive for nuclear PARP expression. PARP (poly (ADP-ribose) polymerase) is a
family of enzymes involved in base excision repair (BER), which is important for
the repair of DNA single-strand breaks (Hoeijmakers, 2001). Cells defective in HR
rely more on other DNA damage repair pathways, such as e.g. BER or NHEJ.
Furthermore, defects in PARP1, a member of the PARP family, are known to induce
the formation of DNA lesions that need to be repaired by the HR pathway (Schultz
et al, 2003). For this reason, a combination of defects in both BER and HR repair is
lethal for the cell. Such a synergistic effect has been exploited in a therapeutic
approach known as “synthetic lethality”. The best known “synthetic lethality”
therapeutic approach used in breast cancer treatment utilizes a class of molecules
called  PARP  inhibitors  to  specifically  target  tumors  harbouring  mutations  in  HR
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genes, such as BRCA1 and BRCA2 (Farmer et al, 2005). The fact that RAD51C-
associated mammary carcinomas express high levels of nuclear PARP, suggests
that treatment with PARP inhibitors may result in a therapeutic benefit for patients
carrying RAD51C mutations.
To compare mammary tumors isolated from Rad51c/p53/K14cre females to
the RAD51C-associated human breast cancers described in the study by
Gevensleben at al., we followed a similar immunohistochemical approach by using
a panel of markers routinely used in human pathology (II, Fig. 3, Fig. 4 and Suppl.
Fig. 1). The following table (Table 9) lists the markers used and their expression in
our analyses. For the purpose of direct comparison, the expression levels of the
same markers in human RAD51C-associated breast cancers is reported in the table.
Table 9. Immuhohistochemical profile of Rad51c mutant tumors.
marker
RAD51C-human
(Gevensleben et al,
2014)
Rad51c/p53/K14cre p53/K14cre
Keratin 14 Negative Low (<30%) Negative
Keratin 18 Positive High (50-70%) Moderate (30-50%)
ER Positive High (50-70%) Low (<30%)
PR Positive Moderate (30-50%) Low (<30%)
HER2/Neu Negative Negative Negative
Ki67 < 20% Moderate (30-50%) High (50-70%)
γH2Ax n.a. High (50-70%) Moderate (30-50%)
TUNEL n.a. Low (<30%) Negative
E-cadherin Positive Moderate (30-50%) Moderate (30-50%)
P-cadherin Negative n.a. n.a.
Vimentin n.a. Low (<30%) High (50-70%)
P53 Negative n.a. n.a.
PARP Positive n.a. n.a.
p-Met n.a. Negative Very high (>70%)
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We found that Rad51c/p53/K14cre mammary tumors were characterized by
low expression of the basal marker Keratin 14.  This observation is contrary to the
fact that the deletion of Rad51c originally occurs in cells expressing Keratin 14. On
the other hand, the luminal Keratin 18 was moderately to highly expressed in
Rad51c-mutant mammary tumors, suggesting a luminal-like classification. In
addition, Rad51c/p53/K14cre mammary tumors were estrogen and progesterone
receptor positive, but HER2 negative. A similar expression pattern was observed
in human RAD51C-related tumors. In contrast, p53/K14cre tumors either lacked or
showed low expression of hormone receptors and HER2, consistent with a triple-
negative basal phenotype.
In line with our findings from preputial glands, apoptosis, assessed by
TUNEL assay, did not affect Rad51c/p53/K14cre mammary tumors, despite high
levels of DNA damage (II, Suppl. Fig. 1). Nevertheless, double mutant carcinomas
showed a rather low proliferation index, which is also characteristic of human
RAD51C-associated breast cancers. The low proliferation initially seemed
paradoxical, given the markedly short tumor-free survival revealed in Rad51c
knock-out females. However, the presence of squamous differentiation in most
mouse mammary tumors (II, Fig. 1F) suggested that these malignancies arose from
ductal epithelial progenitors and had an initial rapid growth phase.  This growth
phase was likely supported by the dense vascular network observed in double
mutant tumors (II, Fig. 1C), but the lack of RAD51C inevitably triggered cellular
keratinization. The result was development of moderately differentiated, luminal-
like adenosquamous carcinomas, consistent with the classification of RAD51C-
mutated human breast cancers. Accordingly, mouse tumors expressed high levels
of the epithelial marker E-cadherin, while being essentially negative for
mesenchymal markers such as Vimentin and p-Met (phosphorylated Met proto-
oncogene), the active form of Met (II, Fig. 4). The complete absence of this
receptor, which is commonly associated with EMT (Lee et al, 2006), was another
indication that Rad51c/p53/K14cre mammary tumors retain an epithelial phenotype,
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and possibly do not form metastases. In contrast, p-Met was highly expressed in
p53-mutant tumors, as already revealed by the presence of Met amplification in
75% of mammary carcinomas isolated from p53/K14cre females (II, Fig. 4).
Taken together, these results indicates that Rad51c/p53/K14cre mammary
tumors closely resemble breast cancers from RAD51C deleterious germ-line
mutation carriers. Keeping this observation in mind, the mouse model generated
in this study provides a system for functional studies that will certainly shed light
on the mechanisms behind Rad51c-mediated mammary tumorigenesis and open
the door to targeted therapies for RAD51C breast cancer patients.
4.5 Role of p53 in mammary glands (II-III)
TP53 is the most commonly mutated tumor suppressor in both human and mouse
cancers. Germ-line mutations of the gene cause Li-Fraumeni syndrome, a rare
autosomal dominant disease that predisposes patients to soft tissue sarcomas,
gliomas, haematological malignancies, and breast and endometrial carcinomas,
especially during childhood and early adulthood (Pantziarka, 2013). In particular,
50% of female Li-Fraumeni syndrome patients develop breast cancer by the age of
60 years (Masciari et al, 2012). While point mutations of TP53 are found in all breast
cancer subtypes, large scale deletions and truncations of the genes are mainly
found among basal-like triple negative breast cancers (The Cancer Genome Atlas
Network, 2012), an observation that is consistent with the classification of
mammary carcinomas developed by Trp53-deficient female mice (Jonkers et al,
2001). In mice, complete p53 knock-out causes developmental abnormalities and
embryonic lethality especially in female embryos, suggesting a role for p53 in
development (Sah et al, 1995).  Interesting, a developmental role has been
reported for at least one other member of the p53 family: p63. Specifically, one
isoform of p63, TAp63, is required during embryogenesis and wound healing and
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is retained in adult tissues only by oocytes and B cells. The other isoform, ΔNp63,
is expressed in the basal layer of several epithelial tissues, including mammary
epithelium, and is required for stem cell maintenance and differentiation (Di Como
et al, 2002; Bamberger et al, 2005; Petitjean et al, 2005; Suh et al, 2006). These
observations suggest that p53 could also have a role in development and that
different cell types might have different requirements for this tumor suppressor.
Based on the previously reported observations with p53, we decided to
investigate the effect of loss of Trp53 in mouse mammary epithelial cells (mMECs).
To this end, we isolated primary mMECs from wild-type and Trp53 ko/ko females and
cultured them in vitro for up to 14 days. Then, we examined the expression of
Keratin 18 and ΔNp63 as markers of luminal and basal cells, respectively. We found
that wild-type mMECs expressed high levels of Keratin 18 for the initial six days of
culture, after which all cells lost the luminal marker and began to express ΔNp63,
switching to a basal phenotype. However, both luminal and basal markers were
lost by culture day 12, when mMECs acquired a spindloid phenotype and started to
express the mesenchymal marker Vimentin (III, Fig. 1 and 2). Interestingly, we
noted that ΔNp63 did not initially disappear from the cells, but became localized
to nucleoli, which are known to be involved in cell cycle control, stress responses,
aging and ubiquitin-mediated protein degradation (Latonen et al, 2011).  On the
other hand, in Trp53 ko/ko mMECs, Keratin 18 was retained longer, while ΔNp63
became detectable later, suggesting that the presence of p53 may normally
antagonize luminal differentiation. A similar phenomenon has been described for
BRCA1: loss of BRCA1 causes basal-like breast cancer despite Brca1 mutations
arising from luminal progenitors (Liu et al, 2008; Molyneaux et al, 2010). We
demonstrated that siRNA (small interfering RNA)-mediated inactivation of BRCA1
in MCF7 cells, a human luminal mammary epithelial cell line, induced upregulation
of ΔNp63, both at the mRNA and protein level (III, Fig. 5) as well as a shift towards
a basal phenotype. Conversely, genetic deletion of TP53 in the basal MCF10A cell
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line induced upregulation of Keratin 18 and translocation of ΔNp63 to nucleoli,
where it became inactivated, leading to basal-to-luminal differentiation (III, Fig. 6).
However,  in our mouse models the Cre-mediated deletion of Trp53 and/or
Rad51c occurs in progenitor cells,  and not in already committed basal  or luminal
cells. As a result, mammary tumors derived from p53/K14cre females did not show
luminal differentiation, but expressed high levels of the mesenchymal marker
Vimentin and the EMT marker p-Met (II, Fig. 4), consistent with a basal-like triple
negative phenotype. On the other hand, Rad51c/p53/K14cre tumors were Keratin
18-positive and retained an epithelial phenotype, suggesting that RAD51C
counteracts the TRP53-antagonizing effect against luminal differentiation.
Alternatively, RAD51C might be directly required for maintenance of basal cells and
its loss could trigger a shift towards luminal differentiation.
4.6 Loss of Rad51c causes senescence, centrosome
amplification and nuclear aberrations (I-II)
In order to shed light on mechanisms leading to sebaceous and mammary
tumorigenesis in Rad51c/p53/K14cre mice and to assess the degree of their genomic
instability, we first decided to delete Rad51c and/or Trp53 in vitro in mouse
keratinocytes and human epithelial mammary cells. However, we failed to obtain
keratinocytes, and thus proceeded with primary mouse embryonic fibroblasts
(MEFs).
4.6.1 Loss of Rad51c in primary MEFs (I)
We isolated primary MEFs, carrying floxed alleles of Rad51c, from which we
generated three different groups corresponding to our three different mouse
cohorts. In the first group, Rad51c was  deleted  using  an  AdenoCre  virus;  in  the
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second group, TRP53 expression was knocked-down by transducing the cells with
a lentiviral shRNA (short interfering RNA) construct targeting Trp53; in the third
group, both Rad51c and Trp53 were deleted using a combination of AdenoCre and
shRNA viruses. A fourth group was left uninfected and used as wild-type control.
All cells were exposed to 5 Gy of ionizing radiation, to induce DNA damage, and
allowed to recover for four hours before further processing. We assessed the
presence of DNA damage and HR by immunofluorescence detection of γH2Ax and
RAD51 foci, respectively. As previously reported (Kuznetsov et al, 2009), deletion
of Rad51c prevented the formation of RAD51 foci, although DNA damage was
present (I, Suppl. Fig. 3). This observation suggests a defective HR, which the
additional loss of Trp53 failed to restore. As expected, Rad51c-deficient MEFs
underwent apoptosis, which was mediated by Trp53, based on the observation
that double-mutant fibroblasts stained negative for cleaved Caspase 3 (I, Fig. 5). In
addition, an increased number of Rad51c knock-out MEFs stained positive for β-
galactosidase (SA-β-Gal) (I, Fig. 5), a marker associated with cellular senescence
(Dimri et al, 1995). Senescence is essentially a growth arrest and can be induced by
p53 in response to DNA damage (Schmitt et al, 2007) or in response to oncogene
activation (Sarkisian et al, 2007). Terminal differentiation, such as keratinization,
can be considered a senescence event, because differentiating cells effectively
stop proliferating. In this regard, we propose that, analogous to the loss of Rad51c
in preputial glands causing terminal differentiation of sebocytes into
keratinocytes, loss of Rad51c in MEFs leads to their growth arrest by senescence (I,
Fig. 5C). In both cases, Trp53 is suspected to mediate the process, because a
concomitant deletion of the gene prevented keratinization in preputial sebocytes
and attenuated senescence in primary fibroblasts.
However, the most interesting finding came from analysis of the nuclear
morphology of mutant MEFs.  Specifically, Rad51c mutant cells revealed a sharp
increase in anaphase bridges, multinucleated cells and micronuclei (I, Fig. 5I-L),
which are known to be caused by chromosome end-to-end fusions and acentric
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chromosomes that fail to segregate during cellular mitosis (Fenech et al, 2011). The
concomitant deletion of Trp53 only exacerbated this phenotype, as observed by
the fact that double mutant MEFs had a higher proliferation index.
4.6.2 Loss of RAD51C in human epithelial mammary cells (II)
One  of  the  aims  of  this  study  was  to  identify  mechanisms  of Rad51c-mediated
tumorigenesis in mammary cells, especially keeping in mind that RAD51C is a breast
cancer predisposition gene in humans. Therefore, we utilized the same approach
used for the study in MEFs (section 4.6.1) in the human non-transformed mammary
epithelial cell line MCF10A and its isogenic TP53 knock-out clone. To this end, we
silenced RAD51C with a specific siRNA and used a non-targeting siRNA as control.
Cells were exposed to 5 Gy of ionizing radiation and processed 24 hours later. As
reported in MEFs (I, Fig. 5), silencing of RAD51C in MCF10A cells caused radiation-
induced senescence, which was prevented in a TP53-deficient background (II, Fig.
5B and D). We also found the same nuclear abnormalities that characterized the
Rad51c-deficient fibroblasts (II,  Fig.  5I-N),  indicating  that  loss  of Rad51c causes
gross chromosomal aberrations in tissues or cells of different origin. Since the
presence of anaphase bridges and micronuclei suggested a mitotic defect, we
used pericentrin to visualize mitotic centrosomes. Consistent with a role of
RAD51C  in  centrosome  maintenance  (Renglin  Lindh  et  al,  2007),  we  found  that
silencing of RAD51C led to formation of multipolar mitoses in 15% of mutant cells as
a result of centrosome amplification (II, Fig. 5F). Given the higher proliferation
index of TP53-deficient MCF10A, the portion of multipolar mitoses after RAD51C
silencing reached 30% in these cells (II, Fig. 5H).
Altogether, the nuclear aberrations found in both RAD51C-deficient MEFs
and human epithelial mammary cells are a clear indication of a faulty genome
stability maintenance which, in our Rad51c/p53 mouse model, results in both
sebaceous and mammary tumorigenesis. In addition, since Rad51c-deficient
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mouse mammary tumors histologically resemble their human counterparts, we
hypothesize that genome instability is also the trigger for tumorigenesis in
RAD51C-mutated breast cancers.
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4.7 Proposed model for RAD51C-mediated tumorigenesis
In conclusion, we described that loss of RAD51C causes detrimental genome
instability, which elicits p53-mediated responses such as cell cycle arrest, apoptosis
and senescence. As a result of the synergy, loss of both RAD51C and TP53 leads to
tumor formation. The following figures propose a schematic model for Rad51c-
mediated tumorigenesis in mouse mammary (Figure 18) and sebaceous glands
(Figure 19) and illustrate the nuclear aberrations characteristic of RAD51C-deficient
mouse and human cells (Figure 20).
Figure 18: Proposed model for Trp53- and Rad51c-mediated tumorigenesis in
mammary glands.   A: Schematic representation of mammary cells differentiation. B:
Loss of Trp53 in K14+ progenitors leads to basal-like solid carcinomas with a latency of
11 months. C: Loss of Rad51c in the same progenitors leads to luminal-like and
adenosquamous carcinomas with a shorter latency (6 months).
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Figure 19: Proposed model for Rad51c-mediated tumorigenesis in preputial glands.   A:
schematic representation of sebaceous differentiation. B: Effect of loss of Rad51c in
sebocyte precursor cells. C: Effect of loss of Rad51c in committed sebocytes.
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Figure 20: In vitro loss of RAD51C causes radiation-induced apoptosis and senescence
(p53-mediated), and impairs cellular proliferation. In addition, RAD51C-deficient cells
are characterized by centrosome amplifications and nuclear aberrations,  which the
concomitant inactivation of TP53 cannot prevent.
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5 CONCLUSIONS AND FUTURE PERSPECTIVES
RAD51C is a well-known component of the cellular DNA repair machinery.
However, its functions go beyond pure recombinational repair as it facilitates both
intra-S  and  G2/M  checkpoint  control  via  activation  of  CHK2.   Furthermore,  it  is
required for telomere protection and prevention of telomere erosion and
chromosome end-to-end fusion.  Finally, it prevents centrosome amplification and
formation of multipolar mitoses.
Like other genes involved in DNA damage responses, mutations in RAD51C
result in tumors in humans. RAD51C is nowadays established as one of the novel
hereditary breast and ovarian cancer predisposition genes, although there are
discrepancies between different studies on whether RAD51C is  mainly  a  breast
cancer or an ovarian cancer susceptibility gene. The percentage of mammary
tumors that carry deleterious mutations in the gene represents, at the moment, a
small proportion of all diagnosed breast cancers, but the numbers are destined to
grow for two reasons. First, the existence of established registers for familiar
breast and ovarian cancers facilitates the screening for RAD51C mutations in
individuals who already tested negative for mutations in BRCA1 and BRCA2. Second,
the association of RAD51C mutations with breast cancer susceptibility increases the
research efforts to find a suitable cure for this new category of cancer patients.
Prior to our studies, we knew that spontaneous loss of Rad51c leads to the
formation of epithelial-derived tumors in mice, including mammary carcinomas,
but the DH model left some important questions unanswered. Is the deletion of
Rad51c enough to induce tumorigenesis? How does Rad51c loss synergize with
Trp53? Do Rad51c-mutated mouse tumors recapitulate features of human RAD51C-
associated breast cancers? If so, how can we shed light on how to treat these
patients?
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We attempted to address these questions by generating a conditional
knock-out model, with which we concluded that loss of Rad51c is not sufficient to
trigger tumorigenesis and requires inactivation of Trp53, highlighting a synergy
between these two genes. Furthermore, we used ex vivo functional studies to
investigate this synergy and found that loss of Rad51c leads to tumor formation by
inducing genomic instability, which is one of the hallmarks of cancer development.
We also determined that lack of Trp53 is a prerequisite for the survival and
proliferation of damaged cells. Finding signs of genome instability in different cell
types, both in mouse and human, led us to conclude that Rad51c is a bona fide
mammalian tumor suppressor.
When we started to analyse mammary tumors from Rad51c/p53 mutant
mice, we did not have any information about the pathophysiology of RAD51C-
associated breast cancers. However, as clinical reports grew in number, we found
that the most remarkable finding from our study was the close resemblance
between mammary carcinomas of these two mammalian species, which is usually
difficult to achieve when trying to reproduce a human disease in a transgenic
mouse model in hindsight.  The discovery of such similarities between murine and
human mammary tumors and the presence of the same nuclear aberrations across
species suggest that findings from the mouse model can be applied to humans and
vice versa. In this regard, we already know that Rad51c-mutant cells from various
organisms possess a selective sensitivity to certain compounds used in
chemothepeutic regimes, such as PARP inhibitors and platinum agents. Moreover,
a pilot study of xenografted RAD51C-mutant cancer cell lines in mice showed a
promising anti-tumoral activity of the oral PARP inhibitor Olaparib (Min et al.,
2013), already used to treat breast cancer patients with mutations in the
homologous recombination genes BRCA1 and BRCA2. It is therefore possible that
RAD51C-mutated tumors could respond as well to PARP inhibitors.
Taken together, our work not only gathered and bolstered the scattered
information on the involvement of RAD51C in tumor formation, it provided new
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evidence which allowed us to finally establish Rad51c as a tumor suppressor gene
with a special role in mammary tumorigenesis. More importantly, the finding that
murine tumors possess the same features of human carcinomas opens the door
for experimenting with targeted therapies that could prove beneficial in the
treatment of human RAD51C-associated breast cancers. In addition, the fact that
Rad51c-mutant females develop in situ carcinomas that are detected as early as
four months of age creates an opportunity for the development of both an early
diagnostic and intervention tool for the management of human patients carrying
RAD51C mutations.
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